Cytotoxic CD8+ T cells in cancer and cancer immunotherapy
The functions of, and interactions between, the innate and adaptive immune systems are vital for anticancer immunity. Cytotoxic T cells expressing cell-surface CD8 are the most powerful effectors in the anticancer immune response and form the backbone of current successful cancer immunotherapies. Im...
Gespeichert in:
| Veröffentlicht in: | British journal of cancer Jg. 124; H. 2; S. 359 - 367 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
London
Nature Publishing Group UK
19.01.2021
Nature Publishing Group |
| Schlagworte: | |
| ISSN: | 0007-0920, 1532-1827, 1532-1827 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | The functions of, and interactions between, the innate and adaptive immune systems are vital for anticancer immunity. Cytotoxic T cells expressing cell-surface CD8 are the most powerful effectors in the anticancer immune response and form the backbone of current successful cancer immunotherapies. Immune-checkpoint inhibitors are designed to target immune-inhibitory receptors that function to regulate the immune response, whereas adoptive cell-transfer therapies use CD8
+
T cells with genetically modified receptors—chimaeric antigen receptors—to specify and enhance CD8
+
T-cell functionality. New generations of cytotoxic T cells with genetically modified or synthetic receptors are being developed and evaluated in clinical trials. Furthermore, combinatory regimens might optimise treatment effects and reduce adverse events. This review summarises advances in research on the most prominent immune effectors in cancer and cancer immunotherapy, cytotoxic T cells, and discusses possible implications for future cancer treatment. |
|---|---|
| AbstractList | The functions of, and interactions between, the innate and adaptive immune systems are vital for anticancer immunity. Cytotoxic T cells expressing cell-surface CD8 are the most powerful effectors in the anticancer immune response and form the backbone of current successful cancer immunotherapies. Immune-checkpoint inhibitors are designed to target immune-inhibitory receptors that function to regulate the immune response, whereas adoptive cell-transfer therapies use CD8
T cells with genetically modified receptors-chimaeric antigen receptors-to specify and enhance CD8
T-cell functionality. New generations of cytotoxic T cells with genetically modified or synthetic receptors are being developed and evaluated in clinical trials. Furthermore, combinatory regimens might optimise treatment effects and reduce adverse events. This review summarises advances in research on the most prominent immune effectors in cancer and cancer immunotherapy, cytotoxic T cells, and discusses possible implications for future cancer treatment. The functions of, and interactions between, the innate and adaptive immune systems are vital for anticancer immunity. Cytotoxic T cells expressing cell-surface CD8 are the most powerful effectors in the anticancer immune response and form the backbone of current successful cancer immunotherapies. Immune-checkpoint inhibitors are designed to target immune-inhibitory receptors that function to regulate the immune response, whereas adoptive cell-transfer therapies use CD8+ T cells with genetically modified receptors—chimaeric antigen receptors—to specify and enhance CD8+ T-cell functionality. New generations of cytotoxic T cells with genetically modified or synthetic receptors are being developed and evaluated in clinical trials. Furthermore, combinatory regimens might optimise treatment effects and reduce adverse events. This review summarises advances in research on the most prominent immune effectors in cancer and cancer immunotherapy, cytotoxic T cells, and discusses possible implications for future cancer treatment. The functions of, and interactions between, the innate and adaptive immune systems are vital for anticancer immunity. Cytotoxic T cells expressing cell-surface CD8 are the most powerful effectors in the anticancer immune response and form the backbone of current successful cancer immunotherapies. Immune-checkpoint inhibitors are designed to target immune-inhibitory receptors that function to regulate the immune response, whereas adoptive cell-transfer therapies use CD8 + T cells with genetically modified receptors—chimaeric antigen receptors—to specify and enhance CD8 + T-cell functionality. New generations of cytotoxic T cells with genetically modified or synthetic receptors are being developed and evaluated in clinical trials. Furthermore, combinatory regimens might optimise treatment effects and reduce adverse events. This review summarises advances in research on the most prominent immune effectors in cancer and cancer immunotherapy, cytotoxic T cells, and discusses possible implications for future cancer treatment. The functions of, and interactions between, the innate and adaptive immune systems are vital for anticancer immunity. Cytotoxic T cells expressing cell-surface CD8 are the most powerful effectors in the anticancer immune response and form the backbone of current successful cancer immunotherapies. Immune-checkpoint inhibitors are designed to target immune-inhibitory receptors that function to regulate the immune response, whereas adoptive cell-transfer therapies use CD8+ T cells with genetically modified receptors-chimaeric antigen receptors-to specify and enhance CD8+ T-cell functionality. New generations of cytotoxic T cells with genetically modified or synthetic receptors are being developed and evaluated in clinical trials. Furthermore, combinatory regimens might optimise treatment effects and reduce adverse events. This review summarises advances in research on the most prominent immune effectors in cancer and cancer immunotherapy, cytotoxic T cells, and discusses possible implications for future cancer treatment.The functions of, and interactions between, the innate and adaptive immune systems are vital for anticancer immunity. Cytotoxic T cells expressing cell-surface CD8 are the most powerful effectors in the anticancer immune response and form the backbone of current successful cancer immunotherapies. Immune-checkpoint inhibitors are designed to target immune-inhibitory receptors that function to regulate the immune response, whereas adoptive cell-transfer therapies use CD8+ T cells with genetically modified receptors-chimaeric antigen receptors-to specify and enhance CD8+ T-cell functionality. New generations of cytotoxic T cells with genetically modified or synthetic receptors are being developed and evaluated in clinical trials. Furthermore, combinatory regimens might optimise treatment effects and reduce adverse events. This review summarises advances in research on the most prominent immune effectors in cancer and cancer immunotherapy, cytotoxic T cells, and discusses possible implications for future cancer treatment. |
| Author | Christensen, Jan Pravsgaard Gögenur, Ismail Raskov, Hans Orhan, Adile |
| Author_xml | – sequence: 1 givenname: Hans orcidid: 0000-0001-8126-1920 surname: Raskov fullname: Raskov, Hans email: raskov@mail.dk organization: Center for Surgical Science, Zealand University Hospital – sequence: 2 givenname: Adile surname: Orhan fullname: Orhan, Adile organization: Center for Surgical Science, Zealand University Hospital, Department of Biomedical Sciences, University of Copenhagen – sequence: 3 givenname: Jan Pravsgaard surname: Christensen fullname: Christensen, Jan Pravsgaard organization: Department of Immunology and Microbiology, University of Copenhagen – sequence: 4 givenname: Ismail surname: Gögenur fullname: Gögenur, Ismail organization: Center for Surgical Science, Zealand University Hospital, Department of Clinical Medicine, University of Copenhagen |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32929195$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kUFP3DAQha0KVBbaP9ADitQLEgqM7UnsXCpVC22RkLjQs-V4HTBK7MVOUPff42V328KBk235e09v5h2SPR-8JeQLhTMKXJ4npEjrEhiUQAFliR_IjFaclVQysUdmACBKaBgckMOUHvKzASk-kgPOGtbQppqRZr4awxj-OFPML-RpcVsY2_epcL4w2hsbC-0Xu6sbhsmH8d5GvVx9Ivud7pP9vD2PyO8fl7fzX-X1zc-r-ffr0qDAsRRoatOaTlgNwiJajS1A23Y1NVVtKtFhp3NEig2C0QvEVjNouVlIbi3X_Ih82_gup3awC2P9GHWvltENOq5U0E69_vHuXt2FJyVkxSnj2eBkaxDD42TTqAaX1lNqb8OUFENkEiUVNKNf36APYYo-j5cpIfL6aFVn6vj_RH-j7LaaAbkBTAwpRdsp40Y9urAO6HpFQa0LVJsCVS5QvRSoMEvZG-nO_V0R34hShv2djf9iv6N6Bvp7rIY |
| CitedBy_id | crossref_primary_10_3389_fonc_2022_851766 crossref_primary_10_1002_art_43244 crossref_primary_10_1016_j_copbio_2022_102799 crossref_primary_10_1007_s00520_023_07968_0 crossref_primary_10_1016_j_annonc_2023_04_005 crossref_primary_10_1016_j_mehy_2025_111679 crossref_primary_10_1007_s10068_024_01595_z crossref_primary_10_3389_fonc_2023_1202750 crossref_primary_10_1002_ijgo_70360 crossref_primary_10_3389_fgene_2022_903393 crossref_primary_10_3389_fimmu_2021_657326 crossref_primary_10_3389_fimmu_2025_1537947 crossref_primary_10_1016_j_biopha_2024_117265 crossref_primary_10_1186_s40364_025_00807_w crossref_primary_10_3389_fimmu_2022_916594 crossref_primary_10_1073_pnas_2424709122 crossref_primary_10_3389_fgene_2022_805961 crossref_primary_10_1158_2326_6066_CIR_23_0486 crossref_primary_10_1016_j_humgen_2025_201473 crossref_primary_10_1016_j_canlet_2025_217865 crossref_primary_10_1186_s40168_024_01804_1 crossref_primary_10_1093_pnasnexus_pgad405 crossref_primary_10_1186_s12929_023_00989_1 crossref_primary_10_1002_adfm_202310623 crossref_primary_10_3390_biom13050874 crossref_primary_10_3390_cells13100864 crossref_primary_10_32604_biocell_2023_030281 crossref_primary_10_1021_acscentsci_4c00579 crossref_primary_10_1016_j_cyto_2025_156912 crossref_primary_10_3389_fimmu_2024_1379376 crossref_primary_10_1016_j_tranon_2025_102524 crossref_primary_10_1186_s41065_023_00307_7 crossref_primary_10_1186_s12879_024_09046_0 crossref_primary_10_1136_bmjopen_2024_097802 crossref_primary_10_1038_s41598_023_42824_5 crossref_primary_10_1089_cmb_2023_0278 crossref_primary_10_3390_ijms25168899 crossref_primary_10_1002_cnr2_1779 crossref_primary_10_1016_j_adcanc_2025_100147 crossref_primary_10_1021_acsomega_5c00693 crossref_primary_10_1186_s40792_023_01606_x crossref_primary_10_31083_FBL27929 crossref_primary_10_3389_fimmu_2023_1151632 crossref_primary_10_1007_s00262_025_04030_2 crossref_primary_10_1158_2159_8290_CD_24_0861 crossref_primary_10_3389_fimmu_2025_1524842 crossref_primary_10_1016_j_critrevonc_2024_104389 crossref_primary_10_1088_1478_3975_ac2e72 crossref_primary_10_1080_2162402X_2025_2526444 crossref_primary_10_1016_j_cell_2024_04_015 crossref_primary_10_1002_pol_20210955 crossref_primary_10_3389_fcell_2023_1266537 crossref_primary_10_3389_fimmu_2024_1288240 crossref_primary_10_1002_cam4_70986 crossref_primary_10_1016_j_heliyon_2024_e32258 crossref_primary_10_3390_genes13050840 crossref_primary_10_1093_cei_uxae127 crossref_primary_10_1172_JCI180080 crossref_primary_10_2174_1381612829666230721122011 crossref_primary_10_3389_fmed_2024_1391843 crossref_primary_10_1016_j_compbiomed_2022_105988 crossref_primary_10_1007_s00259_022_05903_9 crossref_primary_10_3390_biom13091377 crossref_primary_10_1007_s00262_022_03221_5 crossref_primary_10_1016_j_brainresbull_2023_02_016 crossref_primary_10_1136_bmjopen_2023_073372 crossref_primary_10_1016_j_ccell_2024_03_007 crossref_primary_10_1016_j_heliyon_2024_e37998 crossref_primary_10_1016_j_jtbi_2025_112231 crossref_primary_10_3390_biom13121705 crossref_primary_10_1016_j_heliyon_2024_e37511 crossref_primary_10_1016_j_cyto_2024_156822 crossref_primary_10_1080_2162402X_2023_2269634 crossref_primary_10_1016_j_arbres_2024_07_020 crossref_primary_10_3390_jcm13185409 crossref_primary_10_1016_j_apmt_2024_102299 crossref_primary_10_1371_journal_ppat_1011982 crossref_primary_10_1016_j_jep_2023_117183 crossref_primary_10_3389_fimmu_2025_1560778 crossref_primary_10_1016_j_biopha_2023_114976 crossref_primary_10_3389_fcell_2024_1403122 crossref_primary_10_3389_fonc_2022_1065716 crossref_primary_10_3389_fimmu_2024_1382538 crossref_primary_10_1080_13543784_2023_2249814 crossref_primary_10_3390_cancers14133095 crossref_primary_10_1016_j_ijbiomac_2025_147665 crossref_primary_10_1007_s12032_025_02746_w crossref_primary_10_1016_j_bbcan_2023_188905 crossref_primary_10_1016_j_intimp_2024_111696 crossref_primary_10_3389_fimmu_2022_945980 crossref_primary_10_1111_jcmm_18092 crossref_primary_10_1007_s12094_024_03661_8 crossref_primary_10_1007_s11538_025_01433_1 crossref_primary_10_3390_ijms25031725 crossref_primary_10_1002_ange_202216142 crossref_primary_10_1002_cam4_5119 crossref_primary_10_1016_j_tox_2024_153971 crossref_primary_10_5306_wjco_v15_i11_1383 crossref_primary_10_1016_j_canlet_2023_216192 crossref_primary_10_3390_ijms24010147 crossref_primary_10_3389_fmolb_2022_878353 crossref_primary_10_1038_s42256_024_00913_8 crossref_primary_10_1016_j_acthis_2024_152171 crossref_primary_10_3390_nu15163638 crossref_primary_10_1186_s12929_023_00912_8 crossref_primary_10_1002_ctd2_166 crossref_primary_10_1016_j_biopha_2024_117045 crossref_primary_10_3389_fimmu_2025_1655176 crossref_primary_10_3389_fonc_2022_927298 crossref_primary_10_7717_peerj_17667 crossref_primary_10_1186_s12885_025_13438_z crossref_primary_10_3390_cancers16071431 crossref_primary_10_1080_17435889_2025_2500906 crossref_primary_10_3390_cancers17050749 crossref_primary_10_1002_adtp_202400430 crossref_primary_10_1186_s12915_023_01658_3 crossref_primary_10_1007_s10549_024_07504_6 crossref_primary_10_1016_j_heliyon_2024_e33144 crossref_primary_10_2174_0122106812372775250207074104 crossref_primary_10_1016_j_bbcan_2025_189353 crossref_primary_10_1158_2326_6066_CIR_24_0071 crossref_primary_10_3389_fimmu_2022_861559 crossref_primary_10_1038_s41540_024_00486_7 crossref_primary_10_1097_JS9_0000000000001582 crossref_primary_10_1158_2326_6066_CIR_23_0092 crossref_primary_10_1038_s41598_024_84469_y crossref_primary_10_1016_j_jfma_2024_03_003 crossref_primary_10_1136_jitc_2023_008368 crossref_primary_10_1097_CM9_0000000000003738 crossref_primary_10_1002_cam4_5530 crossref_primary_10_1172_JCI181775 crossref_primary_10_1007_s00262_025_04145_6 crossref_primary_10_1016_j_rmed_2022_107093 crossref_primary_10_1080_08982104_2023_2298901 crossref_primary_10_3389_fonc_2022_883197 crossref_primary_10_3390_jpm14101033 crossref_primary_10_3390_vaccines10081370 crossref_primary_10_1186_s12935_024_03211_w crossref_primary_10_3389_fimmu_2023_1118637 crossref_primary_10_1007_s11694_022_01444_9 crossref_primary_10_1002_adma_202509880 crossref_primary_10_1016_j_intimp_2024_113447 crossref_primary_10_1007_s10616_025_00780_0 crossref_primary_10_1016_j_jpha_2025_101254 crossref_primary_10_1016_j_jss_2022_08_040 crossref_primary_10_1016_j_biopha_2022_113740 crossref_primary_10_1016_j_addr_2021_114035 crossref_primary_10_3390_ijms26188788 crossref_primary_10_3390_cancers15092500 crossref_primary_10_1016_j_molmed_2024_02_004 crossref_primary_10_1038_s41467_025_58094_w crossref_primary_10_3389_fimmu_2024_1504220 crossref_primary_10_1136_jitc_2021_004420 crossref_primary_10_3390_cimb46070420 crossref_primary_10_3390_biomedicines9101349 crossref_primary_10_3390_cancers15143729 crossref_primary_10_1097_MD_0000000000026674 crossref_primary_10_3389_fimmu_2024_1336246 crossref_primary_10_3390_ijms26072923 crossref_primary_10_3389_fsurg_2022_1015263 crossref_primary_10_1038_s41598_024_68789_7 crossref_primary_10_1089_rej_2023_0015 crossref_primary_10_1016_j_biopha_2022_112661 crossref_primary_10_3390_cancers13184683 crossref_primary_10_3390_cancers15194797 crossref_primary_10_1016_j_modpat_2022_100012 crossref_primary_10_1155_2022_6267851 crossref_primary_10_1016_j_biomaterials_2024_122788 crossref_primary_10_1002_advs_202414233 crossref_primary_10_1016_j_ebiom_2024_105043 crossref_primary_10_1080_10255842_2025_2453941 crossref_primary_10_1002_anie_202307656 crossref_primary_10_1136_jitc_2022_004974 crossref_primary_10_1016_j_isci_2023_106143 crossref_primary_10_3389_fimmu_2024_1382192 crossref_primary_10_1016_j_tranon_2024_102211 crossref_primary_10_1016_j_oraloncology_2023_106570 crossref_primary_10_1080_08830185_2024_2333275 crossref_primary_10_1158_1078_0432_CCR_22_3743 crossref_primary_10_1016_j_lungcan_2022_05_010 crossref_primary_10_3389_fimmu_2025_1542669 crossref_primary_10_3390_ijms26104482 crossref_primary_10_1016_j_intimp_2022_108555 crossref_primary_10_3389_fimmu_2021_800951 crossref_primary_10_1038_s41568_025_00820_z crossref_primary_10_3390_pharmaceutics16091177 crossref_primary_10_1055_a_2554_4861 crossref_primary_10_3389_fcell_2023_1274361 crossref_primary_10_3390_ph17050636 crossref_primary_10_1002_advs_202501623 crossref_primary_10_1007_s12026_025_09648_z crossref_primary_10_3389_fcell_2024_1369597 crossref_primary_10_3390_cancers14235951 crossref_primary_10_1016_j_immuni_2025_05_001 crossref_primary_10_1038_s41420_024_02182_1 crossref_primary_10_1097_HC9_0000000000000209 crossref_primary_10_1038_s41401_025_01541_7 crossref_primary_10_3233_CBM_220464 crossref_primary_10_3389_fonc_2025_1469982 crossref_primary_10_1016_j_isci_2024_109979 crossref_primary_10_1109_JSSC_2024_3435736 crossref_primary_10_1016_j_biopha_2024_117468 crossref_primary_10_1158_0008_5472_CAN_24_2289 crossref_primary_10_1016_j_radonc_2023_110030 crossref_primary_10_1002_adfm_202416813 crossref_primary_10_3390_biom12111652 crossref_primary_10_1016_j_cellsig_2023_111011 crossref_primary_10_1016_j_nantod_2022_101696 crossref_primary_10_3390_cells11233911 crossref_primary_10_1186_s40364_023_00465_w crossref_primary_10_3390_cancers14163999 crossref_primary_10_4014_jmb_2408_08026 crossref_primary_10_3390_ijms26136076 crossref_primary_10_1007_s12094_024_03594_2 crossref_primary_10_3389_fimmu_2023_1198972 crossref_primary_10_1016_j_biopha_2025_118600 crossref_primary_10_1016_j_jid_2025_07_021 crossref_primary_10_1038_s41467_025_59529_0 crossref_primary_10_3390_cancers16183231 crossref_primary_10_3390_ijms241411504 crossref_primary_10_1038_s43856_022_00197_2 crossref_primary_10_3389_fimmu_2022_1075260 crossref_primary_10_3389_fimmu_2025_1621585 crossref_primary_10_1016_j_cej_2025_163715 crossref_primary_10_1098_rsos_240718 crossref_primary_10_1186_s13046_022_02590_0 crossref_primary_10_1016_j_addr_2023_114840 crossref_primary_10_1016_j_cell_2024_03_011 crossref_primary_10_1186_s12906_025_05020_8 crossref_primary_10_3390_ncrna9060070 crossref_primary_10_1016_j_pbiomolbio_2025_07_002 crossref_primary_10_1038_s41388_024_03191_1 crossref_primary_10_1002_adfm_202424205 crossref_primary_10_1038_s41565_025_01909_0 crossref_primary_10_1016_j_biomaterials_2024_122740 crossref_primary_10_3389_fimmu_2023_1277695 crossref_primary_10_3390_cells12111495 crossref_primary_10_3390_cancers14071749 crossref_primary_10_3390_genes14081599 crossref_primary_10_1186_s12967_023_04606_5 crossref_primary_10_3389_fimmu_2024_1376962 crossref_primary_10_3390_ijms231911362 crossref_primary_10_3389_fimmu_2023_1202725 crossref_primary_10_1080_2162402X_2022_2120676 crossref_primary_10_3389_fonc_2023_1046774 crossref_primary_10_3390_cells13030213 crossref_primary_10_1080_22221751_2024_2387448 crossref_primary_10_3389_fimmu_2023_1337333 crossref_primary_10_3389_fonc_2023_1321326 crossref_primary_10_1136_jitc_2021_004047 crossref_primary_10_3390_cancers16030636 crossref_primary_10_3389_fphar_2023_1146840 crossref_primary_10_1038_s41467_025_57697_7 crossref_primary_10_1016_j_phrs_2024_107122 crossref_primary_10_1158_1078_0432_CCR_23_0258 crossref_primary_10_1002_cbf_70013 crossref_primary_10_3390_ijms241612900 crossref_primary_10_1007_s12274_024_6589_2 crossref_primary_10_3390_ijms25189938 crossref_primary_10_1016_j_intimp_2025_114664 crossref_primary_10_3390_cancers16061136 crossref_primary_10_1186_s12887_024_04731_0 crossref_primary_10_1186_s12935_023_02966_y crossref_primary_10_3389_fimmu_2024_1283364 crossref_primary_10_1007_s00432_023_05156_5 crossref_primary_10_1007_s12272_024_01516_y crossref_primary_10_1039_D4NR02692F crossref_primary_10_1007_s11538_024_01323_y crossref_primary_10_3390_ijms25073976 crossref_primary_10_1016_j_heliyon_2024_e37288 crossref_primary_10_3390_biomedicines11112941 crossref_primary_10_3390_cancers14030689 crossref_primary_10_1186_s12885_025_13912_8 crossref_primary_10_3389_fmed_2022_896494 crossref_primary_10_1002_cti2_1499 crossref_primary_10_1186_s40364_023_00534_0 crossref_primary_10_1080_19420862_2025_2531223 crossref_primary_10_3389_fimmu_2025_1481366 crossref_primary_10_1002_adma_202209966 crossref_primary_10_1016_j_soard_2023_02_016 crossref_primary_10_1038_s41576_022_00553_x crossref_primary_10_3390_medicina59040728 crossref_primary_10_1002_ange_202307656 crossref_primary_10_1371_journal_pone_0297397 crossref_primary_10_1016_j_jaci_2022_10_011 crossref_primary_10_3389_fimmu_2025_1596583 crossref_primary_10_1016_j_prp_2022_154289 crossref_primary_10_3389_fimmu_2024_1328263 crossref_primary_10_1002_adhm_202302374 crossref_primary_10_14712_fb2024070040196 crossref_primary_10_1007_s00432_024_05983_0 crossref_primary_10_1039_D3BM00555K crossref_primary_10_1002_wsbm_1539 crossref_primary_10_3390_ijms24087359 crossref_primary_10_1038_s41598_025_06296_z crossref_primary_10_1016_j_intimp_2022_109016 crossref_primary_10_3389_fimmu_2022_1011590 crossref_primary_10_1016_j_phrs_2025_107668 crossref_primary_10_1038_s42256_024_00973_w crossref_primary_10_1007_s12094_024_03580_8 crossref_primary_10_1186_s12879_025_10932_4 crossref_primary_10_3390_jpm13020359 crossref_primary_10_1158_1078_0432_CCR_23_1137 crossref_primary_10_3389_fimmu_2024_1331641 crossref_primary_10_1002_iid3_727 crossref_primary_10_1186_s13000_023_01338_4 crossref_primary_10_1016_j_prp_2022_154295 crossref_primary_10_1016_j_smim_2021_101485 crossref_primary_10_1007_s12282_023_01507_9 crossref_primary_10_1038_s41392_022_01175_9 crossref_primary_10_3390_v13071408 crossref_primary_10_3390_biomedicines13082018 crossref_primary_10_1016_j_apsb_2025_07_017 crossref_primary_10_1002_cmdc_202100260 crossref_primary_10_3389_fgene_2022_923768 crossref_primary_10_1002_adfm_202414368 crossref_primary_10_1007_s11538_024_01389_8 crossref_primary_10_1155_2022_5803077 crossref_primary_10_1007_s12032_022_01939_x crossref_primary_10_1038_s41590_023_01645_4 crossref_primary_10_1371_journal_pone_0266827 crossref_primary_10_1016_j_ebiom_2022_104268 crossref_primary_10_1002_anie_202216142 crossref_primary_10_1016_j_intimp_2023_109722 crossref_primary_10_3389_fimmu_2023_1238861 crossref_primary_10_1016_j_critrevonc_2023_104102 crossref_primary_10_3389_fgene_2022_1006938 crossref_primary_10_3390_biomedicines13010168 crossref_primary_10_3390_brainsci15080833 crossref_primary_10_3389_fimmu_2024_1379613 crossref_primary_10_1155_crom_7637337 crossref_primary_10_1159_000541881 crossref_primary_10_1002_adfm_202425286 crossref_primary_10_1136_jitc_2023_007082 crossref_primary_10_1186_s12885_023_11808_z crossref_primary_10_1016_j_intimp_2023_110722 crossref_primary_10_1002_adma_202412654 crossref_primary_10_1093_micmic_ozad044 crossref_primary_10_1002_advs_202204335 crossref_primary_10_1016_j_imbio_2024_152844 crossref_primary_10_1590_1519_6984_250575 crossref_primary_10_1016_j_compbiomed_2024_107956 crossref_primary_10_3390_cells14080620 crossref_primary_10_1136_jitc_2024_009111 crossref_primary_10_1186_s41231_024_00161_3 crossref_primary_10_3389_fcell_2024_1514595 crossref_primary_10_1093_jimmun_vkaf165 crossref_primary_10_1136_jitc_2024_010554 crossref_primary_10_1038_s41416_023_02558_7 crossref_primary_10_1002_mco2_471 crossref_primary_10_2174_0115665232305409240918040639 crossref_primary_10_1007_s12672_025_02031_2 crossref_primary_10_1007_s12672_024_01638_1 crossref_primary_10_3389_fimmu_2024_1456030 crossref_primary_10_1128_mbio_02256_25 crossref_primary_10_1007_s10637_025_01538_3 crossref_primary_10_1016_j_cej_2025_163206 crossref_primary_10_1016_j_bbcan_2022_188720 crossref_primary_10_1080_1547691X_2023_2176952 crossref_primary_10_3390_ijms25084208 crossref_primary_10_2147_JIR_S362619 crossref_primary_10_3389_fimmu_2025_1521086 crossref_primary_10_1016_j_lfs_2024_122525 crossref_primary_10_1186_s12967_023_03901_5 crossref_primary_10_3390_cells13110964 crossref_primary_10_2147_JIR_S403370 crossref_primary_10_3389_fimmu_2024_1382842 crossref_primary_10_3389_fonc_2021_768918 crossref_primary_10_4155_fmc_2021_0332 crossref_primary_10_1002_ctm2_70150 crossref_primary_10_3390_vetsci10090541 crossref_primary_10_1210_clinem_dgae702 crossref_primary_10_3390_ijms26052061 crossref_primary_10_1039_D4NR01780C crossref_primary_10_1007_s13721_025_00580_8 crossref_primary_10_1172_JCI177824 crossref_primary_10_1007_s13534_025_00499_z crossref_primary_10_1038_s41598_025_10452_w crossref_primary_10_1097_RLU_0000000000006098 crossref_primary_10_1186_s12885_022_10140_2 crossref_primary_10_1002_1878_0261_13261 crossref_primary_10_1080_1744666X_2024_2356747 crossref_primary_10_3390_vaccines12090955 crossref_primary_10_1186_s12885_022_09526_z crossref_primary_10_1093_jimmun_vkaf125 crossref_primary_10_1186_s12967_024_05309_1 crossref_primary_10_3389_fcell_2022_900418 crossref_primary_10_1016_j_drup_2023_101040 crossref_primary_10_1007_s00262_021_02949_w crossref_primary_10_3390_pharmaceutics15071821 crossref_primary_10_1016_j_biopha_2025_118579 crossref_primary_10_3390_immuno5010008 crossref_primary_10_1038_s41579_023_00973_4 crossref_primary_10_3389_fphar_2024_1349459 crossref_primary_10_3390_life14101246 crossref_primary_10_1038_s41416_024_02909_y crossref_primary_10_1186_s12943_025_02255_4 crossref_primary_10_1016_j_intimp_2024_111936 crossref_primary_10_1016_j_jhepr_2024_101304 crossref_primary_10_1016_j_isci_2024_111338 crossref_primary_10_3390_cancers15030835 crossref_primary_10_3390_cancers17111887 crossref_primary_10_3389_fimmu_2025_1581964 crossref_primary_10_1016_j_intimp_2025_115339 crossref_primary_10_1039_D2FO03181G crossref_primary_10_1158_2767_9764_CRC_24_0310 crossref_primary_10_1016_j_labinv_2024_102148 crossref_primary_10_3389_fphar_2024_1426974 crossref_primary_10_1038_s41467_025_57586_z crossref_primary_10_1002_iid3_1011 crossref_primary_10_1007_s10495_024_02006_8 crossref_primary_10_1016_j_prp_2024_155743 crossref_primary_10_3390_ijms25126792 crossref_primary_10_1016_j_intimp_2023_111464 crossref_primary_10_1080_17474086_2022_2091542 crossref_primary_10_1136_jitc_2022_006116 crossref_primary_10_1097_MD_0000000000033732 crossref_primary_10_1038_s41467_023_42303_5 crossref_primary_10_1158_0008_5472_CAN_24_3748 crossref_primary_10_3390_biomedicines11061517 crossref_primary_10_3390_ijms26136337 crossref_primary_10_3390_microorganisms12010230 crossref_primary_10_1016_j_omto_2023_09_001 crossref_primary_10_26599_NR_2025_94907712 crossref_primary_10_1186_s12885_023_11014_x crossref_primary_10_1093_jimmun_vkae002 crossref_primary_10_3390_cancers16234094 crossref_primary_10_1016_j_intimp_2022_109030 crossref_primary_10_1158_0008_5472_CAN_23_4066 crossref_primary_10_1088_1758_5090_ad847f crossref_primary_10_3390_cancers15072024 crossref_primary_10_3390_cancers17101658 crossref_primary_10_1038_s41417_023_00629_8 crossref_primary_10_1080_1120009X_2024_2443701 crossref_primary_10_3389_fimmu_2023_1104711 crossref_primary_10_1038_s41467_024_48397_9 crossref_primary_10_1016_j_pmatsci_2024_101347 crossref_primary_10_1021_acsmedchemlett_5c00245 crossref_primary_10_3389_fimmu_2022_1006665 crossref_primary_10_3389_fonc_2024_1380648 crossref_primary_10_1038_s43018_024_00734_z crossref_primary_10_3390_molecules29143388 crossref_primary_10_3389_fimmu_2023_1227797 crossref_primary_10_3390_ijms26146778 crossref_primary_10_3390_pharmaceutics15041143 crossref_primary_10_2139_ssrn_3805194 crossref_primary_10_1007_s00405_021_06879_2 crossref_primary_10_1038_s41598_024_66075_0 crossref_primary_10_3390_ijms26104737 crossref_primary_10_1016_j_phrs_2025_107674 crossref_primary_10_3390_ijms252413569 crossref_primary_10_3389_fgene_2022_934830 crossref_primary_10_1016_j_celrep_2024_114377 crossref_primary_10_1002_cmdc_202300305 crossref_primary_10_3390_cancers15102721 crossref_primary_10_1016_j_ijpharm_2021_120849 crossref_primary_10_3389_fimmu_2022_1024039 crossref_primary_10_3389_fimmu_2022_835690 crossref_primary_10_3390_cells14151220 crossref_primary_10_3390_ijms25126501 crossref_primary_10_3389_fimmu_2024_1457189 crossref_primary_10_1186_s12929_025_01182_2 crossref_primary_10_1186_s40824_023_00465_9 crossref_primary_10_1016_j_xcrm_2025_102188 crossref_primary_10_1007_s10555_021_09974_2 crossref_primary_10_3390_ijms252413308 crossref_primary_10_1007_s00262_023_03377_8 crossref_primary_10_1016_j_actbio_2025_08_048 crossref_primary_10_1182_blood_2023023166 crossref_primary_10_1016_j_ijbiomac_2022_09_106 crossref_primary_10_1007_s13258_024_01612_9 crossref_primary_10_1038_s41467_024_52170_3 crossref_primary_10_1038_s41416_025_03013_5 crossref_primary_10_1158_2326_6066_CIR_24_0230 crossref_primary_10_1089_jir_2023_0043 crossref_primary_10_1155_2024_5537948 crossref_primary_10_3390_vaccines13020205 crossref_primary_10_5306_wjco_v15_i11_1412 crossref_primary_10_3389_fimmu_2024_1497788 crossref_primary_10_1097_MD_0000000000042187 crossref_primary_10_3390_immuno5030029 crossref_primary_10_3390_jpm12050807 crossref_primary_10_3390_ijms26136388 crossref_primary_10_1007_s12026_025_09593_x crossref_primary_10_1093_icb_icac022 crossref_primary_10_3389_fendo_2023_1182776 crossref_primary_10_1371_journal_pcbi_1013127 crossref_primary_10_1002_iub_70028 crossref_primary_10_1016_j_ejmech_2023_115465 crossref_primary_10_1158_0008_5472_CAN_22_1837 crossref_primary_10_1016_j_labinv_2024_102072 crossref_primary_10_1093_hmg_ddad187 crossref_primary_10_3390_ijms25179463 crossref_primary_10_1002_smll_202409154 crossref_primary_10_1016_j_lfs_2023_121569 crossref_primary_10_3390_ijms232415780 crossref_primary_10_1016_j_molimm_2023_06_004 crossref_primary_10_3390_cancers13112667 crossref_primary_10_1016_j_actbio_2025_07_035 crossref_primary_10_3390_cancers14071681 crossref_primary_10_1016_j_pan_2025_08_003 crossref_primary_10_1016_j_ymthe_2025_06_040 crossref_primary_10_56871_RBR_2025_85_15_008 crossref_primary_10_3390_radiation2010001 crossref_primary_10_1007_s00277_024_05820_x crossref_primary_10_1080_15384047_2024_2355705 crossref_primary_10_1186_s12943_023_01809_8 crossref_primary_10_1002_advs_202500825 crossref_primary_10_1002_cam4_7212 crossref_primary_10_3389_fphar_2025_1582540 crossref_primary_10_1016_j_jconrel_2022_07_017 crossref_primary_10_1186_s40824_023_00350_5 crossref_primary_10_1002_jmv_28084 crossref_primary_10_2147_BLCTT_S327016 crossref_primary_10_1038_s41467_024_50474_y crossref_primary_10_1093_pcmedi_pbad021 crossref_primary_10_1177_11795549221126249 crossref_primary_10_1016_j_humimm_2024_110836 crossref_primary_10_1007_s10555_025_10244_8 crossref_primary_10_3389_fmicb_2023_1270158 crossref_primary_10_1016_j_addr_2022_114239 crossref_primary_10_3389_fimmu_2025_1609175 crossref_primary_10_1080_13880209_2024_2349042 crossref_primary_10_1007_s10238_024_01541_7 crossref_primary_10_1016_j_bbrc_2024_149921 crossref_primary_10_1007_s12035_025_05243_3 crossref_primary_10_1016_j_chembiol_2024_04_007 crossref_primary_10_3390_cimb46060334 crossref_primary_10_3389_fimmu_2021_669474 crossref_primary_10_3389_fimmu_2025_1604310 crossref_primary_10_3389_fbioe_2022_944518 crossref_primary_10_3390_ijms23062904 crossref_primary_10_3389_fonc_2022_769124 crossref_primary_10_1007_s11010_024_04970_w crossref_primary_10_1158_2326_6066_CIR_23_0573 crossref_primary_10_1002_cbin_11655 crossref_primary_10_1007_s00262_025_04140_x crossref_primary_10_3389_fonc_2022_858479 crossref_primary_10_3390_cancers16081589 crossref_primary_10_3390_metabo13060734 crossref_primary_10_1038_s44321_025_00225_3 crossref_primary_10_1002_ctm2_70472 crossref_primary_10_3390_cancers15225444 crossref_primary_10_1186_s13550_024_01142_1 crossref_primary_10_1016_j_intimp_2021_107895 crossref_primary_10_3390_cancers17152448 crossref_primary_10_1186_s12876_025_04003_w crossref_primary_10_3389_fgene_2022_919829 crossref_primary_10_1186_s40164_024_00524_4 crossref_primary_10_1016_j_bone_2024_117328 crossref_primary_10_1002_cam4_70899 crossref_primary_10_1038_s41598_024_54273_9 crossref_primary_10_1186_s12935_022_02821_6 crossref_primary_10_1007_s11626_024_00881_8 crossref_primary_10_1097_SHK_0000000000001967 crossref_primary_10_1016_j_ccr_2025_216846 crossref_primary_10_1016_j_jconrel_2022_09_061 crossref_primary_10_1515_jtim_2024_0033 crossref_primary_10_1016_j_saa_2025_126464 crossref_primary_10_1245_s10434_025_18260_2 crossref_primary_10_1016_j_biopha_2022_113665 crossref_primary_10_1186_s12885_024_12039_6 crossref_primary_10_1155_2023_5532617 crossref_primary_10_1016_j_stem_2024_04_018 crossref_primary_10_1186_s12935_022_02769_7 crossref_primary_10_1038_s41467_023_41335_1 crossref_primary_10_3389_fimmu_2023_1137880 crossref_primary_10_1016_j_phrs_2023_106988 crossref_primary_10_1002_adfm_202414918 crossref_primary_10_1186_s12943_025_02305_x crossref_primary_10_3390_cells14070488 crossref_primary_10_1007_s11033_025_10494_3 crossref_primary_10_1016_j_jot_2024_12_004 crossref_primary_10_1038_s41418_024_01369_4 crossref_primary_10_3389_fimmu_2022_921894 crossref_primary_10_1016_j_micpath_2024_106955 crossref_primary_10_1007_s13346_024_01557_2 crossref_primary_10_1038_s41388_025_03517_7 crossref_primary_10_3389_fgene_2022_974416 crossref_primary_10_1007_s11431_023_2574_0 crossref_primary_10_1016_j_coisb_2021_100361 crossref_primary_10_1016_j_ejphar_2023_176239 crossref_primary_10_3390_ijms241813913 crossref_primary_10_1172_JCI191070 crossref_primary_10_1002_advs_202202702 crossref_primary_10_1021_acsnano_5c04836 crossref_primary_10_1158_2326_6066_CIR_24_1055 crossref_primary_10_1186_s12885_023_11636_1 crossref_primary_10_1002_adhm_202301517 crossref_primary_10_3389_fimmu_2023_1298891 crossref_primary_10_1016_j_cellimm_2023_104755 crossref_primary_10_1016_j_clgc_2024_102142 crossref_primary_10_1016_j_prp_2024_155266 crossref_primary_10_1016_j_zemedi_2023_04_007 crossref_primary_10_1002_smll_202406950 crossref_primary_10_3389_fphar_2022_950156 crossref_primary_10_1007_s12032_025_02647_y crossref_primary_10_1016_j_nano_2025_102817 crossref_primary_10_3389_fphar_2023_1146280 crossref_primary_10_1007_s00262_024_03881_5 crossref_primary_10_25122_jml_2025_0014 crossref_primary_10_1016_j_drup_2024_101159 crossref_primary_10_1007_s00262_024_03674_w crossref_primary_10_1098_rsob_240392 crossref_primary_10_3389_fimmu_2024_1505896 crossref_primary_10_3390_pharmaceutics15072003 crossref_primary_10_3390_pharmaceutics15072004 crossref_primary_10_1038_s41467_025_56275_1 crossref_primary_10_1038_s41598_025_09075_y crossref_primary_10_3389_fimmu_2023_1173379 crossref_primary_10_1016_j_ccell_2023_12_010 crossref_primary_10_1016_j_heliyon_2023_e23541 crossref_primary_10_3390_ijms231911431 crossref_primary_10_1016_j_matbio_2023_04_002 crossref_primary_10_1007_s00432_025_06095_z crossref_primary_10_1016_j_cnsns_2022_106987 crossref_primary_10_3389_fimmu_2025_1559211 crossref_primary_10_1080_1061186X_2024_2384071 crossref_primary_10_3390_ijms26115045 crossref_primary_10_1007_s11033_024_09882_y crossref_primary_10_1016_j_oraloncology_2023_106659 crossref_primary_10_1016_j_ctro_2022_11_005 crossref_primary_10_1007_s40487_021_00177_x crossref_primary_10_1016_j_apsb_2024_03_027 crossref_primary_10_3389_fendo_2022_929091 crossref_primary_10_3390_cimb47090690 crossref_primary_10_1002_adbi_202200031 crossref_primary_10_1002_advs_202300548 crossref_primary_10_3389_fcell_2025_1515681 crossref_primary_10_1038_s41467_024_46377_7 crossref_primary_10_1002_adfm_202100437 crossref_primary_10_1007_s00262_024_03754_x crossref_primary_10_1038_s41467_024_45340_w crossref_primary_10_3390_cells13040305 crossref_primary_10_1007_s00262_023_03504_5 crossref_primary_10_1186_s12979_023_00374_4 crossref_primary_10_1186_s13020_025_01146_6 crossref_primary_10_1186_s12967_024_05675_w crossref_primary_10_1016_j_nantod_2023_101831 crossref_primary_10_1038_s42003_025_08568_w crossref_primary_10_3390_cancers17162672 crossref_primary_10_3389_fmed_2024_1364778 crossref_primary_10_1016_j_jff_2024_106408 crossref_primary_10_1002_cac2_12487 crossref_primary_10_3389_fmolb_2025_1566551 crossref_primary_10_1016_j_prp_2025_156226 crossref_primary_10_1016_j_advms_2022_09_004 crossref_primary_10_1016_j_biopha_2024_116660 crossref_primary_10_3389_fonc_2022_995929 crossref_primary_10_1016_j_heliyon_2023_e19261 crossref_primary_10_1039_D3SC05539F crossref_primary_10_1016_j_it_2023_07_005 crossref_primary_10_1016_j_bbcan_2024_189123 crossref_primary_10_1016_j_ejphar_2021_174365 crossref_primary_10_1186_s12967_023_04616_3 crossref_primary_10_1016_j_cej_2024_152467 crossref_primary_10_2147_OTT_S410693 crossref_primary_10_3389_fgene_2022_851373 crossref_primary_10_3390_ijms241411673 crossref_primary_10_1016_j_ejmech_2024_116638 crossref_primary_10_1002_advs_202401287 crossref_primary_10_1016_j_jddst_2023_105050 crossref_primary_10_3390_biomedicines13061297 crossref_primary_10_1016_j_prp_2025_156216 crossref_primary_10_1016_j_semcancer_2022_03_007 crossref_primary_10_1038_s43856_025_00958_9 crossref_primary_10_1039_D4BM00241E crossref_primary_10_3389_fphys_2022_1078512 crossref_primary_10_3389_fimmu_2022_1059725 crossref_primary_10_1016_j_cej_2024_154877 crossref_primary_10_1111_1759_7714_15426 crossref_primary_10_3389_fimmu_2024_1490505 crossref_primary_10_1007_s10555_024_10212_8 crossref_primary_10_3389_fgene_2025_1521663 crossref_primary_10_1007_s40610_024_00161_0 crossref_primary_10_3389_fonc_2022_878923 crossref_primary_10_3390_bioengineering11040303 crossref_primary_10_14712_fb2024070030123 crossref_primary_10_1016_j_cpet_2024_05_002 crossref_primary_10_1096_fj_202200269RR crossref_primary_10_1016_j_cell_2025_06_048 crossref_primary_10_1016_j_fsi_2022_108456 crossref_primary_10_4014_jmb_2407_07025 crossref_primary_10_3389_fgene_2022_977156 crossref_primary_10_3389_fphar_2024_1289957 crossref_primary_10_1016_j_canlet_2024_217421 crossref_primary_10_1186_s40164_023_00375_5 crossref_primary_10_3390_cancers14163869 crossref_primary_10_1111_imr_13356 crossref_primary_10_2147_JIR_S523194 crossref_primary_10_3390_cancers14153656 crossref_primary_10_3390_vaccines12060649 crossref_primary_10_3390_cells12192404 crossref_primary_10_1007_s00262_025_04022_2 crossref_primary_10_1158_1940_6207_CAPR_25_0023 crossref_primary_10_1002_advs_202301216 crossref_primary_10_3390_biomedicines13051031 crossref_primary_10_3390_cells13181567 crossref_primary_10_3389_fimmu_2025_1530789 crossref_primary_10_3389_fonc_2022_912537 crossref_primary_10_1177_03946320231158025 crossref_primary_10_1007_s12672_024_01195_7 crossref_primary_10_1016_j_prp_2023_154735 crossref_primary_10_1136_jitc_2024_009644 crossref_primary_10_1186_s12876_025_03735_z crossref_primary_10_2147_CMAR_S456717 crossref_primary_10_1038_s41435_023_00198_8 crossref_primary_10_1080_21655979_2021_2019873 crossref_primary_10_1089_vim_2023_0144 crossref_primary_10_3389_fonc_2023_1208140 crossref_primary_10_1016_j_modpat_2025_100809 crossref_primary_10_3389_fimmu_2023_1203929 crossref_primary_10_3389_fsurg_2022_893977 crossref_primary_10_1007_s00281_022_00973_1 crossref_primary_10_35339_msz_2025_94_2_sph crossref_primary_10_1002_adma_202311640 crossref_primary_10_3390_cells13050395 crossref_primary_10_1186_s40164_025_00613_y crossref_primary_10_3389_fphar_2022_995555 crossref_primary_10_1002_mc_23834 crossref_primary_10_1016_j_bbrc_2023_02_039 crossref_primary_10_1515_oncologie_2023_0244 crossref_primary_10_1080_14789450_2024_2428332 crossref_primary_10_1155_2022_9359879 crossref_primary_10_3389_fonc_2023_1127448 crossref_primary_10_1016_j_cytogfr_2022_07_004 crossref_primary_10_1007_s12032_023_02198_0 crossref_primary_10_1038_s41598_025_11450_8 crossref_primary_10_1016_j_ijbiomac_2021_05_073 crossref_primary_10_1186_s12951_023_02106_8 crossref_primary_10_1002_cam4_4791 crossref_primary_10_3389_fphar_2023_1242970 crossref_primary_10_1016_j_bioactmat_2022_07_023 crossref_primary_10_1016_j_intimp_2021_108337 crossref_primary_10_3389_fimmu_2022_887649 crossref_primary_10_1016_j_mam_2023_101239 crossref_primary_10_1016_j_modpat_2023_100223 crossref_primary_10_1177_17588359251320280 crossref_primary_10_1016_j_prp_2023_154707 crossref_primary_10_1038_s42003_025_08339_7 crossref_primary_10_1016_j_imbio_2023_152391 crossref_primary_10_1002_advs_202301661 crossref_primary_10_1002_adhm_202201690 crossref_primary_10_1016_j_omton_2024_200770 crossref_primary_10_1016_j_canlet_2024_216805 crossref_primary_10_3390_cancers13010077 crossref_primary_10_1016_j_nantod_2024_102365 crossref_primary_10_1038_s41416_025_02979_6 crossref_primary_10_1016_j_chembiol_2023_05_003 crossref_primary_10_1002_ijc_34897 crossref_primary_10_1038_s41598_025_01472_7 crossref_primary_10_1080_08923973_2022_2061989 crossref_primary_10_1186_s12885_022_10461_2 crossref_primary_10_1007_s12672_025_02622_z crossref_primary_10_1177_17588359231193732 crossref_primary_10_1021_acscentsci_2c00704 crossref_primary_10_1093_bioinformatics_btae440 crossref_primary_10_1007_s00330_023_10241_x crossref_primary_10_3389_fimmu_2025_1527592 crossref_primary_10_32604_biocell_2023_027209 crossref_primary_10_1016_j_isci_2025_113538 crossref_primary_10_1186_s13059_024_03292_w crossref_primary_10_3233_KCA_230006 crossref_primary_10_1210_endrev_bnae031 crossref_primary_10_3390_pharmaceutics15071788 crossref_primary_10_1039_D4NR00729H crossref_primary_10_1007_s12672_025_02185_z crossref_primary_10_7717_peerj_cs_2239 crossref_primary_10_1002_adhm_202201214 crossref_primary_10_1084_jem_20241417 crossref_primary_10_3389_fimmu_2022_761046 crossref_primary_10_1136_jitc_2025_011815 crossref_primary_10_3389_fimmu_2024_1391840 crossref_primary_10_1016_j_clinre_2024_102510 crossref_primary_10_3390_life13112228 crossref_primary_10_13005_bpj_2798 crossref_primary_10_1016_j_bone_2023_116944 crossref_primary_10_1016_j_gene_2025_149433 crossref_primary_10_1002_adfm_202312360 crossref_primary_10_2147_IJGM_S467179 crossref_primary_10_1155_2022_6343760 crossref_primary_10_1186_s12943_025_02378_8 crossref_primary_10_3390_vaccines12121396 crossref_primary_10_1007_s10238_023_01015_2 crossref_primary_10_1073_pnas_2500019122 crossref_primary_10_1007_s12672_025_02524_0 crossref_primary_10_3389_fimmu_2022_864298 crossref_primary_10_3390_biom14020171 crossref_primary_10_1038_s41435_025_00336_4 crossref_primary_10_3390_ijms24087240 crossref_primary_10_3390_ijms252413697 crossref_primary_10_3389_fimmu_2024_1328145 crossref_primary_10_3390_biomedicines12020262 crossref_primary_10_1158_2767_9764_CRC_24_0281 crossref_primary_10_1158_2326_6066_CIR_24_0320 crossref_primary_10_1371_journal_pone_0324618 crossref_primary_10_1093_oncolo_oyae372 crossref_primary_10_3389_fimmu_2023_1225639 crossref_primary_10_3389_fmed_2022_1055785 crossref_primary_10_1016_j_humimm_2023_03_001 crossref_primary_10_1016_j_jfma_2024_05_007 crossref_primary_10_1007_s00520_025_09280_5 crossref_primary_10_1001_jamanetworkopen_2022_52140 crossref_primary_10_3390_ijms25052953 crossref_primary_10_3923_ijp_2025_259_269 crossref_primary_10_1093_neuonc_noae149 crossref_primary_10_1016_j_jpi_2023_100352 crossref_primary_10_1016_j_xcrm_2025_102252 crossref_primary_10_3389_fimmu_2025_1618393 crossref_primary_10_3389_fonc_2025_1625212 crossref_primary_10_1007_s12672_025_02250_7 crossref_primary_10_1016_j_jconrel_2025_02_065 crossref_primary_10_1080_1750743X_2025_2527019 crossref_primary_10_3389_fimmu_2022_1026954 crossref_primary_10_1007_s00259_022_05998_0 crossref_primary_10_3389_fmed_2025_1558016 crossref_primary_10_1016_j_nantod_2022_101500 crossref_primary_10_3390_vaccines10060879 crossref_primary_10_1002_adbi_202400140 crossref_primary_10_1002_iid3_1351 crossref_primary_10_1186_s13027_025_00673_z crossref_primary_10_1016_j_bcp_2025_117157 crossref_primary_10_1136_jitc_2024_010890 crossref_primary_10_1016_j_bcp_2022_115138 crossref_primary_10_1186_s13062_025_00604_3 crossref_primary_10_7759_cureus_58748 crossref_primary_10_3390_life12050678 crossref_primary_10_1016_j_biomaterials_2025_123615 crossref_primary_10_3389_fimmu_2025_1548234 crossref_primary_10_1002_hep4_1682 crossref_primary_10_1016_j_bioorg_2025_108582 crossref_primary_10_1002_adma_202412563 crossref_primary_10_1016_j_nantod_2025_102672 crossref_primary_10_1016_j_jconrel_2025_02_072 crossref_primary_10_3390_cells10102631 crossref_primary_10_3389_fphar_2022_901563 crossref_primary_10_3390_biomedicines13051202 crossref_primary_10_3390_cancers14215414 crossref_primary_10_1186_s12964_024_01622_w crossref_primary_10_3390_cancers15020366 crossref_primary_10_1016_j_ymthe_2024_08_019 crossref_primary_10_1158_1541_7786_MCR_25_0101 crossref_primary_10_1186_s13046_024_03195_5 crossref_primary_10_3390_cancers15082354 crossref_primary_10_1158_1055_9965_EPI_24_0333 crossref_primary_10_1038_s41392_025_02295_8 crossref_primary_10_1186_s12964_023_01070_y crossref_primary_10_3390_cancers13061440 crossref_primary_10_1016_j_jconrel_2023_12_007 crossref_primary_10_3389_fmed_2021_766960 crossref_primary_10_1016_j_ctro_2025_101018 crossref_primary_10_1371_journal_pone_0305261 crossref_primary_10_3390_arm92060045 crossref_primary_10_1002_mog2_70030 crossref_primary_10_3390_cancers16010081 crossref_primary_10_3389_fonc_2025_1592328 crossref_primary_10_1016_j_pharmthera_2024_108640 crossref_primary_10_1016_j_molmed_2023_03_006 crossref_primary_10_60084_hjas_v3i1_263 crossref_primary_10_1016_j_intimp_2025_114579 crossref_primary_10_1038_s44321_024_00177_0 crossref_primary_10_1089_jir_2024_0099 crossref_primary_10_1371_journal_pone_0327947 crossref_primary_10_3390_cancers16051041 crossref_primary_10_3390_cancers17122022 crossref_primary_10_3390_cancers16101928 crossref_primary_10_1002_1878_0261_13160 crossref_primary_10_1016_j_ejpb_2024_114510 crossref_primary_10_1016_j_ejphar_2023_175721 crossref_primary_10_1038_s41467_024_54139_8 crossref_primary_10_3389_fimmu_2022_898255 crossref_primary_10_1016_j_labinv_2024_102209 crossref_primary_10_1016_j_omto_2023_01_001 crossref_primary_10_1158_2159_8290_CD_22_0907 crossref_primary_10_1016_j_ymeth_2025_07_001 crossref_primary_10_1038_s44319_024_00365_6 crossref_primary_10_1038_s41598_025_85981_5 crossref_primary_10_1016_j_celrep_2024_114632 crossref_primary_10_4103_egjp_egjp_4_25 crossref_primary_10_3389_fimmu_2022_1038340 crossref_primary_10_1007_s10495_023_01925_2 crossref_primary_10_1007_s12672_025_02083_4 crossref_primary_10_3389_fonc_2023_1099811 crossref_primary_10_1038_s41598_025_85892_5 crossref_primary_10_1177_10732748241270583 crossref_primary_10_3390_ijms26031235 crossref_primary_10_4132_jptm_2024_01_31 crossref_primary_10_1007_s12032_024_02564_6 crossref_primary_10_1111_imm_13777 crossref_primary_10_1080_1744666X_2025_2545904 crossref_primary_10_3389_fgene_2024_1522484 crossref_primary_10_1002_cbic_202500440 crossref_primary_10_1186_s12885_023_11233_2 crossref_primary_10_1002_path_6429 crossref_primary_10_1016_j_ijbiomac_2024_131789 crossref_primary_10_3389_fgene_2023_1265866 crossref_primary_10_1016_j_heliyon_2024_e26887 crossref_primary_10_3390_cancers16020308 crossref_primary_10_1002_cam4_6197 crossref_primary_10_1158_2326_6066_CIR_21_0772 crossref_primary_10_1186_s41747_025_00597_8 crossref_primary_10_3389_fcell_2024_1331759 crossref_primary_10_3389_fimmu_2024_1379777 crossref_primary_10_1093_ibd_izaf064 crossref_primary_10_1016_j_rpth_2025_102977 crossref_primary_10_1186_s13058_025_01980_4 crossref_primary_10_1007_s10237_024_01891_x crossref_primary_10_3390_ijms26104821 crossref_primary_10_1038_s41467_022_35238_w crossref_primary_10_1016_j_biopha_2023_114760 crossref_primary_10_3389_fendo_2022_1051076 crossref_primary_10_1016_j_bbrc_2022_06_052 crossref_primary_10_1016_j_ijpharm_2025_125901 crossref_primary_10_1038_s41598_024_64053_0 crossref_primary_10_3390_cancers16172942 crossref_primary_10_1002_smll_202410214 crossref_primary_10_3390_vaccines13020114 crossref_primary_10_1186_s12943_024_02017_8 crossref_primary_10_3390_cancers14215442 crossref_primary_10_1016_j_imbio_2025_153090 crossref_primary_10_1016_j_cmet_2024_01_012 crossref_primary_10_3390_cancers14164020 crossref_primary_10_1007_s11538_024_01400_2 crossref_primary_10_3390_ijms232113424 crossref_primary_10_3390_jpm14070765 crossref_primary_10_1002_path_6448 crossref_primary_10_1038_s41417_021_00367_9 crossref_primary_10_1186_s12951_024_03051_w crossref_primary_10_1186_s40364_024_00610_z crossref_primary_10_3389_fimmu_2023_1276602 crossref_primary_10_1007_s13577_024_01083_w crossref_primary_10_3390_ijms26094393 crossref_primary_10_1177_10781552251324896 crossref_primary_10_1016_j_eururo_2022_04_013 crossref_primary_10_1038_s41541_024_00943_8 crossref_primary_10_1007_s11010_024_05186_8 crossref_primary_10_1515_nanoph_2021_0171 crossref_primary_10_3389_fonc_2021_701738 crossref_primary_10_3390_ijms26125567 crossref_primary_10_3390_vaccines11091503 crossref_primary_10_1016_j_ijbiomac_2024_137061 crossref_primary_10_1016_j_prp_2024_155679 crossref_primary_10_1016_j_apsb_2025_02_022 crossref_primary_10_1080_14737140_2023_2245140 crossref_primary_10_3390_ani13213392 crossref_primary_10_1371_journal_pcbi_1013050 crossref_primary_10_3389_fimmu_2024_1413067 crossref_primary_10_1016_j_intimp_2022_109157 crossref_primary_10_3390_nu17182993 crossref_primary_10_1002_biof_1799 crossref_primary_10_3390_ijms242015398 crossref_primary_10_1016_j_imbio_2022_152314 crossref_primary_10_3389_fgene_2022_917118 crossref_primary_10_1016_j_biomaterials_2025_123233 crossref_primary_10_1016_j_annonc_2024_03_007 crossref_primary_10_1016_j_imlet_2025_107061 crossref_primary_10_1186_s13045_024_01561_6 crossref_primary_10_3390_pharmaceutics15010112 crossref_primary_10_3390_cancers14174083 crossref_primary_10_1002_jcla_24585 crossref_primary_10_1093_pcmedi_pbaf013 crossref_primary_10_1002_adfm_202100088 crossref_primary_10_1002_1878_0261_13793 crossref_primary_10_3389_fphar_2023_1255586 crossref_primary_10_1016_j_biopha_2022_113395 crossref_primary_10_1002_jhbp_12088 crossref_primary_10_1016_j_heliyon_2024_e27329 crossref_primary_10_1016_j_taap_2022_116246 crossref_primary_10_1093_cei_uxad090 crossref_primary_10_4103_jomfp_jomfp_53_24 crossref_primary_10_1002_kjm2_12948 crossref_primary_10_1136_jitc_2022_005592 crossref_primary_10_1186_s13578_025_01432_8 crossref_primary_10_1186_s12885_024_12874_7 crossref_primary_10_1038_s41388_024_03066_5 crossref_primary_10_3892_mmr_2024_13290 crossref_primary_10_1016_j_neo_2024_101091 crossref_primary_10_1016_j_cyto_2023_156334 crossref_primary_10_1016_j_intimp_2023_110457 crossref_primary_10_1016_j_cpt_2022_12_002 crossref_primary_10_3390_cancers14143383 crossref_primary_10_3389_fcell_2022_830208 crossref_primary_10_3390_biom12010132 crossref_primary_10_1080_14728222_2022_2114897 crossref_primary_10_3389_fonc_2025_1511560 crossref_primary_10_3389_fimmu_2024_1428541 crossref_primary_10_3389_fonc_2023_1273516 crossref_primary_10_1038_s41420_024_01960_1 crossref_primary_10_1016_j_omto_2021_11_017 crossref_primary_10_1038_s41416_023_02396_7 crossref_primary_10_1007_s00262_024_03801_7 |
| Cites_doi | 10.1186/1476-4598-11-81 10.1186/s12943-019-1091-2 10.3390/ijms20061283 10.1056/NEJMoa1809615 10.1158/2159-8290.CD-15-1545 10.1073/pnas.1720948115 10.2147/OTT.S150817 10.1038/s41587-019-0192-1 10.1038/s41591-018-0036-4 10.1016/S0002-9440(10)63481-5 10.1158/2159-8290.CD-17-0250 10.1189/jlb.1212621 10.3389/fimmu.2017.01467 10.1158/0008-5472.CAN-16-1311 10.1038/ncomms10823 10.1038/s41573-018-0007-y 10.1001/jamanetworkopen.2019.2535 10.1007/s00345-018-2264-0 10.1016/j.imlet.2018.11.004 10.1158/2326-6066.CIR-14-0161 10.1038/88678 10.1056/NEJMoa1816047 10.1038/s41590-018-0229-5 10.1074/jbc.M114.574319 10.1126/science.aba7365 10.3389/fimmu.2017.00894 10.1016/j.coi.2017.01.005 10.1038/nrd.2018.210 10.1038/s41418-019-0474-7 10.3389/fimmu.2019.02103 10.1126/science.1131078 10.3390/cancers11010002 10.1186/s40425-019-0768-9 10.1158/1078-0432.CCR-07-0674 10.1016/j.it.2018.12.003 10.1038/s41573-019-0051-2 10.1245/s10434-018-6691-3 10.1158/2159-8290.CD-17-1327 10.1056/NEJMoa1809064 10.1016/S1470-2045(19)30823-X 10.1001/jamaoncol.2019.2311 10.1038/ncomms7692 10.4049/jimmunol.1400322 10.1038/s41419-019-1435-2 10.1158/2326-6066.CIR-18-0277 10.1007/s40265-017-0690-8 10.1038/s41598-018-22252-6 10.1038/s42003-020-0848-x 10.1126/science.aaa6204 10.1371/journal.pone.0200725 10.1016/j.cell.2016.01.021 10.1016/j.molcel.2015.01.018 10.1016/j.yexcr.2013.08.003 10.1038/ni.2703 10.1155/2019/5245034 10.1007/s11899-018-0470-x 10.1007/s00262-017-1954-6 10.1016/j.ebiom.2016.10.034 10.1080/14728222.2018.1444753 10.3389/fimmu.2015.00441 10.1128/JVI.00889-12 10.3389/fimmu.2019.01835 10.1038/s41467-018-03347-0 10.1038/42523 10.1200/JCO.2017.76.9901 10.1038/s41467-018-07810-w 10.1038/bjc.2017.220 10.1056/NEJMoa1801005 10.1038/384577a0 10.1073/pnas.0600651103 10.1016/j.ccell.2018.03.012 10.3389/fimmu.2018.01816 10.1189/jlb.1RU0814-382 10.1038/nrclinonc.2014.224 10.1038/cmi.2011.45 10.2217/imt.12.112 10.1093/annonc/mdy551 10.1016/j.molcel.2016.01.009 10.1016/j.cell.2018.11.043 10.1016/j.biopha.2019.108921 10.1016/j.celrep.2014.02.036 10.1186/s12943-019-0982-6 10.1056/NEJMoa1305133 10.1038/s41568-019-0116-x 10.1016/j.cell.2016.01.011 10.3390/cancers12030683 10.2174/1389201019666180418095526 10.1038/s41434-018-0019-6 10.1016/j.immuni.2018.03.004 10.1111/imm.12809 10.1038/nri.2016.80 10.1053/j.gastro.2008.07.016 10.1007/s00281-018-0714-9 10.3389/fonc.2018.00066 10.18632/oncotarget.17232 10.1001/jamanetworkopen.2019.20833 10.1126/science.aaf4405 10.1073/pnas.0801497105 10.1158/1078-0432.CCR-18-1942 10.1038/d41573-019-00072-1 10.1126/science.aau0135 |
| ContentType | Journal Article |
| Copyright | The Author(s), under exclusive licence to Cancer Research UK 2020 The Author(s), under exclusive licence to Cancer Research UK 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s), under exclusive licence to Cancer Research UK 2020 – notice: The Author(s), under exclusive licence to Cancer Research UK 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7TO 7U9 7X7 7XB 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AN0 AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB0 LK8 M0S M1P M7P NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 5PM |
| DOI | 10.1038/s41416-020-01048-4 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland British Nursing Database ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Biological Sciences Health & Medical Collection (Alumni Edition) PQ Medical Database Biological Science Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition British Nursing Index with Full Text ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE ProQuest Central Student CrossRef MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7RV name: Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1532-1827 |
| EndPage | 367 |
| ExternalDocumentID | PMC7853123 32929195 10_1038_s41416_020_01048_4 |
| Genre | Journal Article Review |
| GroupedDBID | --- 0R~ 23N 36B 39C 4.4 406 53G 5GY 5RE 6J9 70F 7RV 7X7 88E 8AO 8C1 8FI 8FJ 8R4 8R5 AACDK AANZL AASML AATNV AAWTL AAYZH AAZLF ABAKF ABLJU ABOCM ABUWG ABZZP ACAOD ACGFO ACGFS ACKTT ACPRK ACRQY ACZOJ ADBBV ADFRT ADHDB AEFQL AEJRE AEMSY AENEX AEVLU AEXYK AFBBN AFKRA AFRAH AFSHS AGAYW AGHAI AGQEE AHMBA AHSBF AIGIU AILAN AJRNO ALFFA ALMA_UNASSIGNED_HOLDINGS AMYLF AN0 AOIJS ASPBG AVWKF AXYYD AZFZN BAWUL BBNVY BENPR BHPHI BKEYQ BKKNO BNQBC BPHCQ BVXVI C6C CCPQU CS3 DIK DNIVK DPUIP DU5 E3Z EAP EBLON EBS EE. EIOEI EMB ESX EX3 F5P FDQFY FEDTE FERAY FIGPU FRJ FSGXE FYUFA GX1 HCIFZ HMCUK HVGLF HYE HZ~ IH2 IWAJR JSO JZLTJ KQ8 M1P M7P NAPCQ NQJWS O9- OK1 P2P PQQKQ PROAC PSQYO Q2X RNT RNTTT ROL RPM SNX SNYQT SOHCF SOJ SRMVM SWTZT TAOOD TBHMF TDRGL TR2 UKHRP W2D WH7 WOW ~02 AAFWJ AAYXX ABBRH ABDBE ABFSG ABRTQ ACSTC AEZWR AFDZB AFFHD AFHIU AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT PJZUB PPXIY PQGLB -Q- .55 .GJ 8WZ A6W ABAWZ ABDBF ACUHS AI. B0M CAG CGR COF CUY CVF EAD EAS EBC EBD ECM EIF EJD EMK EMOBN EPL FIZPM J5H M41 NPM SV3 TUS UDS VH1 X7M Y6R ZGI ~8M 3V. 7TO 7U9 7XB 8FE 8FH 8FK AZQEC DWQXO GNUQQ H94 K9. LK8 PKEHL PQEST PQUKI PRINS 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c474t-74c6cbcf7ea07e44ea4b00bbf61c56c57f4fa92014940cad44ba20b3cd83ee3a3 |
| IEDL.DBID | M7P |
| ISICitedReferencesCount | 1151 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000569286500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0007-0920 1532-1827 |
| IngestDate | Tue Nov 04 01:58:52 EST 2025 Sun Sep 28 09:46:22 EDT 2025 Tue Oct 07 05:19:14 EDT 2025 Thu Apr 03 07:06:45 EDT 2025 Sat Nov 29 02:47:32 EST 2025 Tue Nov 18 22:26:26 EST 2025 Fri Feb 21 02:38:13 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Language | English |
| License | Note This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c474t-74c6cbcf7ea07e44ea4b00bbf61c56c57f4fa92014940cad44ba20b3cd83ee3a3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0001-8126-1920 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC7853123 |
| PMID | 32929195 |
| PQID | 2477090156 |
| PQPubID | 41855 |
| PageCount | 9 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7853123 proquest_miscellaneous_2442848171 proquest_journals_2477090156 pubmed_primary_32929195 crossref_citationtrail_10_1038_s41416_020_01048_4 crossref_primary_10_1038_s41416_020_01048_4 springer_journals_10_1038_s41416_020_01048_4 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-01-19 |
| PublicationDateYYYYMMDD | 2021-01-19 |
| PublicationDate_xml | – month: 01 year: 2021 text: 2021-01-19 day: 19 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | British journal of cancer |
| PublicationTitleAbbrev | Br J Cancer |
| PublicationTitleAlternate | Br J Cancer |
| PublicationYear | 2021 |
| Publisher | Nature Publishing Group UK Nature Publishing Group |
| Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group |
| References | Lanzavecchia, Sallusto (CR34) 2001; 2 Heinhuis, Ros, Kok, Steeghs, Beijnen, Schellens (CR99) 2019; 30 Market, Baxter, Angka, Kennedy, Auer (CR103) 2018; 11 Havel, Chowell, Chan (CR36) 2019; 19 Dolgin (CR95) 2019; 18 Miliotou, Papadopoulou (CR51) 2018; 19 Arasanz, Gato-Cañas, Zuazo, Ibañez-Vea, Breckpot, Kochan (CR31) 2017; 8 Basu, Whitlock, Husson, Le Floc’h, Jin, Oyler-Yaniv (CR17) 2016; 165 Fu, Fu, Cruz, Sengupta, Thomas, Wang (CR19) 2016; 61 Lafitte, Rousseau, Moranvillier, Taillepierre, Peuchant, Guyonnet-Dupérat (CR66) 2012; 11 Peranzoni, Lemoine, Vimeux, Feuillet, Barrin, Kantari-Mimoun (CR79) 2018; 115 Galon, Bruni (CR71) 2019; 18 Angka, Martel, Kilgour, Jeong, Sadiq, de Souza (CR102) 2018; 25 Wellenstein, de Visser (CR1) 2018; 48 Depil, Duchateau, Grupp, Mufti, Poirot (CR50) 2020; 19 Mulcahy Levy, Thorburn (CR94) 2020; 27 Balar, Weber (CR41) 2017; 66 Yang, Yu, Cai, Du, Cai (CR62) 2020; 3 Choi, Yu, Castano, Bouffard, Schmidts, Larson (CR63) 2019; 37 Meng, Hao, He, Li, Zhu (CR88) 2019; 18 Souza-Fonseca-Guimaraes, Cursons, Huntington (CR38) 2019; 40 Garnier, Magnus, Meehan, Kislinger, Rak (CR90) 2013; 319 Davis, Patel (CR40) 2019; 7 Singh, McGuirk (CR96) 2016; 76 Wiedemann, Depoil, Faroudi, Valitutti (CR20) 2006; 103 Qin, Xu, Yi, Yu, Wu, Luo (CR4) 2019; 18 Grywalska, Pasiarski, Góźdź, Roliński (CR30) 2018; 11 Williams, Schonnesen, Zhang, Ma, He, Yamamoto (CR14) 2017; 8 Gandhi, Rodríguez-Abreu, Gadgeel, Esteban, Felip, De Angelis (CR46) 2018; 378 Overman, Lonardi, Wong, Lenz, Gelsomino, Aglietta (CR45) 2018; 36 Khazen, Müller, Gaudenzio, Espinosa, Puissegur, Valitutti (CR21) 2016; 7 Schmidt, Chisamore, Chaney, Maradeo, Anderson, Baltus (CR49) 2020; 3 Roybal, Rupp, Morsut, Walker, McNally, Park (CR60) 2016; 164 Speiser, Ho, Verdeil (CR80) 2016; 16 Joyce, Fearon (CR81) 2015; 348 Joller, Kuchroo (CR27) 2017; 410 Lowe, Mackall, Norry, Amado, Jakobsen, Binder (CR57) 2018; 25 Bettini, Guy, Dash, Vignali, Hamm, Dobbins (CR9) 2014; 193 Towers, Thorburn (CR93) 2016; 14 Norelli, Camisa, Barbiera, Falcone, Purevdorj, Genua (CR59) 2018; 24 Benmebarek, Karches, Cadilha, Lesch, Endres, Kobold (CR54) 2019; 20 Hamid, Robert, Daud, Hodi, Hwu, Kefford (CR39) 2013; 369 Dornmair, Goebels, Weltzien, Wekerle, Hohlfeld (CR22) 2003; 163 Hay, Turtle (CR53) 2017; 77 Li, van der Leun, Yofe, Lubling, Gelbard-Solodkin, van Akkooi (CR26) 2019; 176 Gao, Tormo, Gerth, Wyer, McMichael, Stuart (CR13) 1997; 387 Intlekofer, Thompson (CR35) 2013; 94 Blackburn, Shin, Freeman, Wherry (CR64) 2008; 105 Brazin, Mallis, Das, Feng, Hwang, Wang (CR7) 2015; 6 Patsoukis, Bardhan, Chatterjee, Sari, Liu, Bell (CR32) 2015; 6 Luke, Bao, Sweis, Spranger, Gajewski (CR86) 2019; 25 Rajagopal, Harikumar (CR73) 2018; 8 Singh, McGuirk (CR52) 2020; 21 Chen, Roh, Reuben, Cooper, Spencer, Prieto (CR68) 2016; 6 Zeng, Li, Pan, Lan, Song, Sun (CR74) 2018; 9 Dustin (CR8) 2014; 2 Chiou, Risca, Wang, Yang, Gruner, Kathiria (CR67) 2017; 7 Rankin, Giaccia (CR89) 2016; 352 Shevchenko, Bazhin (CR23) 2018; 9 T.F., H. (CR65) 2013; 14 Cho, Okuma, Al-Rubaye, Intisar, Junghans, Wong (CR61) 2018; 8 Schneider, Downey, Smith, Zinselmeyer, Rush, Brewer (CR33) 2006; 313 Stadtmauer, Fraietta, Davis, Cohen, Weber, Lancaster (CR3) 2020; 367 Tang, Yu, Hubbard-Lucey, Neftelinov, Hodge, Lin (CR97) 2018; 17 Barnes, Amir (CR2) 2017; 117 Kakarla, Song, Gottschalk (CR82) 2012; 4 Horn, Mansfield, Szczęsna, Havel, Krzakowski, Hochmair (CR47) 2018; 379 Othman, Jamal, Abu (CR76) 2019; 10 Furlan, Minowa, Hanagata, Kataoka-Hamai, Kaizuka (CR10) 2014; 289 Lee, Ruppin (CR72) 2019; 5 Grasso, Giannakis, Wells, Hamada, Mu, Quist (CR87) 2018; 8 Lakins, Ghorani, Munir, Martins, Shields (CR84) 2018; 9 Horowitz, Neeman, Sharon, Ben-Eliyahu (CR101) 2015; 12 Overgaard, Jung, Steptoe, Wells (CR5) 2015; 97 Amatore, Gorvel, Olive (CR28) 2018; 22 Ichim, Lopez, Ahmed, Muthalagu, Giampazolias, Delgado (CR92) 2015; 57 Ngoenkam, Schamel, Pongcharoen (CR11) 2018; 153 Vacca, Munari, Tumino, Moretta, Pietra, Vitale (CR6) 2018; 201 Garcia, Scott, Brunmark, Carbone, Peterson, Wilson (CR12) 1996; 384 Sun, Hao, Yang, Zhang, Fu (CR58) 2018; 2018 Trujillo, Sweis, Bao, Luke (CR70) 2018; 6 Pehlivan, Duncan, Lee (CR56) 2018; 13 Brentjens, Santos, Nikhamin, Yeh, Matsushita, La Perle (CR55) 2007; 13 Faia, White, Murphy, Proctor, Pink, Kosmider (CR16) 2018; 13 Thorburn, Andrysik, Staskiewicz, Gump, Maycotte, Oberst (CR91) 2014; 7 Gordy, He (CR18) 2012; 9 Motzer, Penkov, Haanen, Rini, Albiges, Campbell (CR44) 2019; 380 Xue, Yu, Xue, Ge, Zhao, Peng (CR85) 2019; 115 Angelosanto, Blackburn, Crawford, Wherry (CR25) 2012; 86 Haslam, Prasad (CR42) 2019; 2 Thommen, Schumacher (CR69) 2018; 33 Chruściel, Urban-Wójciuk, Arcimowicz, Kurkowiak, Kowalski, Rzyman, Biernat, Montesano (CR98) 2020; 12 Schmid, Adams, Rugo, Schneeweiss, Barrios, Iwata (CR48) 2018; 379 Soria, Beleni, D’Andrea, Resch, Gust, Gontero (CR43) 2018; 36 CR24 Schmidt (CR37) 2019; 41 Zumerle, Molon, Viola (CR15) 2017; 8 Joshi, Durden (CR100) 2019; 2019 Bethmann, Feng, Fox (CR29) 2017; 45 Patel, Fu, Mastio, Dominguez, Purohit, Kossenkov (CR75) 2018; 19 Pinchuk, Saada, Beswick, Boya, Qiu, Mifflin (CR83) 2008; 135 Zhang, Qi, Zhao, Li, Shao, Zhang (CR77) 2019; 10 Monteran, Erez (CR78) 2019; 10 F Amatore (1048_CR28) 2018; 22 E Grywalska (1048_CR30) 2018; 11 S Qin (1048_CR4) 2019; 18 P Schmid (1048_CR48) 2018; 379 DE Speiser (1048_CR80) 2016; 16 S Kakarla (1048_CR82) 2012; 4 MA Lakins (1048_CR84) 2018; 9 P-L Chen (1048_CR68) 2016; 6 A Wiedemann (1048_CR20) 2006; 103 L Gandhi (1048_CR46) 2018; 378 K Faia (1048_CR16) 2018; 13 S Zumerle (1048_CR15) 2017; 8 S-H Chiou (1048_CR67) 2017; 7 JA Joyce (1048_CR81) 2015; 348 AK Singh (1048_CR52) 2020; 21 L Monteran (1048_CR78) 2019; 10 JM Mulcahy Levy (1048_CR94) 2020; 27 AV Balar (1048_CR41) 2017; 66 H Arasanz (1048_CR31) 2017; 8 EV Schmidt (1048_CR49) 2020; 3 ML Bettini (1048_CR9) 2014; 193 S Sun (1048_CR58) 2018; 2018 E Dolgin (1048_CR95) 2019; 18 KL Lowe (1048_CR57) 2018; 25 CS Grasso (1048_CR87) 2018; 8 1048_CR24 S Depil (1048_CR50) 2020; 19 D Garnier (1048_CR90) 2013; 319 RJ Motzer (1048_CR44) 2019; 380 M Market (1048_CR103) 2018; 11 C Gordy (1048_CR18) 2012; 9 J Tang (1048_CR97) 2018; 17 ML Dustin (1048_CR8) 2014; 2 BD Choi (1048_CR63) 2019; 37 JA Trujillo (1048_CR70) 2018; 6 DS Thommen (1048_CR69) 2018; 33 R Basu (1048_CR17) 2016; 165 E Peranzoni (1048_CR79) 2018; 115 H Schneider (1048_CR33) 2006; 313 A Haslam (1048_CR42) 2019; 2 EA Stadtmauer (1048_CR3) 2020; 367 A Lanzavecchia (1048_CR34) 2001; 2 J Galon (1048_CR71) 2019; 18 R Khazen (1048_CR21) 2016; 7 S Patel (1048_CR75) 2018; 19 H Li (1048_CR26) 2019; 176 G T.F. (1048_CR65) 2013; 14 S Joshi (1048_CR100) 2019; 2019 P Vacca (1048_CR6) 2018; 201 AM Intlekofer (1048_CR35) 2013; 94 MD Wellenstein (1048_CR1) 2018; 48 KT Roybal (1048_CR60) 2016; 164 N Othman (1048_CR76) 2019; 10 K Dornmair (1048_CR22) 2003; 163 EV Schmidt (1048_CR37) 2019; 41 M-R Benmebarek (1048_CR54) 2019; 20 KC Garcia (1048_CR12) 1996; 384 MJ Overman (1048_CR45) 2018; 36 SD Blackburn (1048_CR64) 2008; 105 CM Williams (1048_CR14) 2017; 8 J Xue (1048_CR85) 2019; 115 J Thorburn (1048_CR91) 2014; 7 N Patsoukis (1048_CR32) 2015; 6 M Lafitte (1048_CR66) 2012; 11 KC Pehlivan (1048_CR56) 2018; 13 N Joller (1048_CR27) 2017; 410 D Bethmann (1048_CR29) 2017; 45 NH Overgaard (1048_CR5) 2015; 97 M Norelli (1048_CR59) 2018; 24 L Angka (1048_CR102) 2018; 25 TA Barnes (1048_CR2) 2017; 117 JM Angelosanto (1048_CR25) 2012; 86 Z Zeng (1048_CR74) 2018; 9 RJ Brentjens (1048_CR55) 2007; 13 C Rajagopal (1048_CR73) 2018; 8 E Chruściel (1048_CR98) 2020; 12 R Zhang (1048_CR77) 2019; 10 L Horn (1048_CR47) 2018; 379 Q Fu (1048_CR19) 2016; 61 AK Singh (1048_CR96) 2016; 76 M Horowitz (1048_CR101) 2015; 12 F Soria (1048_CR43) 2018; 36 A Miliotou (1048_CR51) 2018; 19 KM Heinhuis (1048_CR99) 2019; 30 O Hamid (1048_CR39) 2013; 369 JH Cho (1048_CR61) 2018; 8 F Souza-Fonseca-Guimaraes (1048_CR38) 2019; 40 J Ngoenkam (1048_CR11) 2018; 153 CG Towers (1048_CR93) 2016; 14 Z Yang (1048_CR62) 2020; 3 AA Davis (1048_CR40) 2019; 7 G Ichim (1048_CR92) 2015; 57 KN Brazin (1048_CR7) 2015; 6 E Rankin (1048_CR89) 2016; 352 KA Hay (1048_CR53) 2017; 77 I Shevchenko (1048_CR23) 2018; 9 G Gao (1048_CR13) 1997; 387 IV Pinchuk (1048_CR83) 2008; 135 JS Lee (1048_CR72) 2019; 5 JJ Luke (1048_CR86) 2019; 25 G Furlan (1048_CR10) 2014; 289 JJ Havel (1048_CR36) 2019; 19 W Meng (1048_CR88) 2019; 18 |
| References_xml | – volume: 11 year: 2012 ident: CR66 article-title: In vivo gene transfer targeting in pancreatic adenocarcinoma with cell surface antigens publication-title: Mol. Cancer doi: 10.1186/1476-4598-11-81 – volume: 18 year: 2019 ident: CR4 article-title: Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4 publication-title: Mol. Cancer doi: 10.1186/s12943-019-1091-2 – volume: 20 start-page: 1283 year: 2019 ident: CR54 article-title: Killing mechanisms of chimeric antigen receptor (CAR) T cells publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms20061283 – volume: 379 start-page: 2108 year: 2018 end-page: 2121 ident: CR48 article-title: Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1809615 – volume: 6 start-page: 827 year: 2016 end-page: 837 ident: CR68 article-title: Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-15-1545 – volume: 115 start-page: E4041 year: 2018 end-page: E4050 ident: CR79 article-title: Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.1720948115 – volume: 11 start-page: 6505 year: 2018 end-page: 6524 ident: CR30 article-title: Immune-checkpoint inhibitors for combating T-cell dysfunction in cancer publication-title: Onco. Targets Ther. doi: 10.2147/OTT.S150817 – volume: 37 start-page: 1049 year: 2019 end-page: 1058 ident: CR63 article-title: CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity publication-title: Nat. Biotechnol. doi: 10.1038/s41587-019-0192-1 – volume: 24 start-page: 739 year: 2018 end-page: 748 ident: CR59 article-title: Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells publication-title: Nat. Med. doi: 10.1038/s41591-018-0036-4 – volume: 163 start-page: 1215 year: 2003 end-page: 1226 ident: CR22 article-title: T-cell-mediated autoimmunity: novel techniques to characterize autoreactive T-cell receptors publication-title: Am. J. Pathol. doi: 10.1016/S0002-9440(10)63481-5 – volume: 7 start-page: 1184 year: 2017 end-page: 1199 ident: CR67 article-title: BLIMP1 induces transient metastatic heterogeneity in pancreatic cancer publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-17-0250 – volume: 94 start-page: 25 year: 2013 end-page: 39 ident: CR35 article-title: At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy publication-title: J. Leukoc. Biol. doi: 10.1189/jlb.1212621 – volume: 8 start-page: 1467 year: 2017 ident: CR15 article-title: Membrane rafts in T cell activation: a spotlight on CD28 costimulation publication-title: Front. Immunol. doi: 10.3389/fimmu.2017.01467 – volume: 76 start-page: 6445 year: 2016 end-page: 64451 ident: CR96 article-title: Allogeneic stem cell transplantation: a historical and scientific overview publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-16-1311 – volume: 7 year: 2016 ident: CR21 article-title: Melanoma cell lysosome secretory burst neutralizes the CTL-mediated cytotoxicity at the lytic synapse publication-title: Nat. Commun. doi: 10.1038/ncomms10823 – volume: 18 start-page: 197 year: 2019 end-page: 218 ident: CR71 article-title: Approaches to treat immune hot, altered and cold tumours with combination immunotherapies publication-title: Nat. Rev. Drug Discov. doi: 10.1038/s41573-018-0007-y – volume: 2 start-page: e192535 year: 2019 end-page: e192535 ident: CR42 article-title: Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs publication-title: JAMA Netw. Open doi: 10.1001/jamanetworkopen.2019.2535 – volume: 36 start-page: 1703 year: 2018 end-page: 1709 ident: CR43 article-title: Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer publication-title: World J. Urol. doi: 10.1007/s00345-018-2264-0 – volume: 201 start-page: 14 year: 2018 end-page: 19 ident: CR6 article-title: Human natural killer cells and other innate lymphoid cells in cancer: friends or foes? publication-title: Immunol. Lett. doi: 10.1016/j.imlet.2018.11.004 – volume: 2 start-page: 1023 year: 2014 end-page: 1033 ident: CR8 article-title: The immunological synapse publication-title: Cancer Immunol. Res. doi: 10.1158/2326-6066.CIR-14-0161 – volume: 2 start-page: 487 year: 2001 end-page: 492 ident: CR34 article-title: Antigen decoding by T lymphocytes: from synapses to fate determination publication-title: Nat. Immunol. doi: 10.1038/88678 – volume: 380 start-page: 1103 year: 2019 end-page: 1115 ident: CR44 article-title: Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1816047 – volume: 19 start-page: 1236 year: 2018 end-page: 1247 ident: CR75 article-title: Unique pattern of neutrophil migration and function during tumor progression publication-title: Nat. Immunol. doi: 10.1038/s41590-018-0229-5 – volume: 289 start-page: 28514 year: 2014 end-page: 28525 ident: CR10 article-title: Phosphatase CD45 both positively and negatively regulates T cell receptor phosphorylation in reconstituted membrane protein clusters publication-title: J. Biol. Chem. doi: 10.1074/jbc.M114.574319 – volume: 367 start-page: eaba7365 year: 2020 ident: CR3 article-title: CRISPR-engineered T cells in patients with refractory cancer publication-title: Science doi: 10.1126/science.aba7365 – volume: 8 start-page: 894 year: 2017 ident: CR14 article-title: Normalized synergy predicts that CD8 co-receptor contribution to T cell receptor (TCR) and pMHC binding decreases as TCR affinity increases in human viral-specific T cells publication-title: Front. Immunol. doi: 10.3389/fimmu.2017.00894 – volume: 45 start-page: 60 year: 2017 end-page: 72 ident: CR29 article-title: Immunoprofiling as a predictor of patient’s response to cancer therapy—promises and challenges publication-title: Curr. Opin. Immunol. doi: 10.1016/j.coi.2017.01.005 – volume: 17 start-page: 854 year: 2018 ident: CR97 article-title: The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors publication-title: Nat. Rev. Drug Discov. doi: 10.1038/nrd.2018.210 – volume: 27 start-page: 843 year: 2020 end-page: 857 ident: CR94 article-title: Autophagy in cancer: moving from understanding mechanism to improving therapy responses in patients publication-title: Cell Death Differ. doi: 10.1038/s41418-019-0474-7 – volume: 10 start-page: 2103 year: 2019 ident: CR76 article-title: Cancer-derived exosomes as effectors of key inflammation-related players publication-title: Front. Immunol. doi: 10.3389/fimmu.2019.02103 – volume: 313 start-page: 1972 year: 2006 end-page: 1975 ident: CR33 article-title: Reversal of the TCR Stop Signal by CTLA-4 publication-title: Science doi: 10.1126/science.1131078 – volume: 11 start-page: 2 year: 2018 ident: CR103 article-title: The potential for cancer immunotherapy in targeting surgery-induced natural killer cell dysfunction publication-title: Cancers doi: 10.3390/cancers11010002 – volume: 7 start-page: 278 year: 2019 ident: CR40 article-title: The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors publication-title: J. Immunother. Cancer doi: 10.1186/s40425-019-0768-9 – volume: 13 start-page: 5426 year: 2007 end-page: 5435 ident: CR55 article-title: Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-07-0674 – volume: 40 start-page: 142 year: 2019 end-page: 158 ident: CR38 article-title: The emergence of natural killer cells as a major target in cancer immunotherapy publication-title: Trends Immunol. doi: 10.1016/j.it.2018.12.003 – volume: 19 start-page: 185 year: 2020 end-page: 199 ident: CR50 article-title: ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges publication-title: Nat. Rev. Drug Discov. doi: 10.1038/s41573-019-0051-2 – volume: 25 start-page: 3747 year: 2018 end-page: 3754 ident: CR102 article-title: Natural killer cell IFNγ secretion is profoundly suppressed following colorectal cancer surgery publication-title: Ann. Surg. Oncol. doi: 10.1245/s10434-018-6691-3 – volume: 8 start-page: 730 year: 2018 end-page: 749 ident: CR87 article-title: Genetic mechanisms of immune evasion in colorectal cancer publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-17-1327 – volume: 379 start-page: 2220 year: 2018 end-page: 2229 ident: CR47 article-title: First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1809064 – volume: 21 start-page: e168 year: 2020 end-page: e178 ident: CR52 article-title: CAR T cells: continuation in a revolution of immunotherapy publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(19)30823-X – volume: 5 start-page: 1614 year: 2019 end-page: 1618 ident: CR72 article-title: Multiomics prediction of response rates to therapies to inhibit programmed cell death 1 and programmed cell death 1 ligand 1 publication-title: JAMA Oncol. doi: 10.1001/jamaoncol.2019.2311 – volume: 6 year: 2015 ident: CR32 article-title: PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation publication-title: Nat. Commun. doi: 10.1038/ncomms7692 – volume: 2018 start-page: 2386187 year: 2018 ident: CR58 article-title: Immunotherapy with CAR-modified T cells: toxicities and overcoming strategies publication-title: J. Immunol. Res. – volume: 193 start-page: 258 year: 2014 end-page: 267 ident: CR9 article-title: Membrane association of the CD3ε signaling domain is required for optimal T cell development and function publication-title: J. Immunol. doi: 10.4049/jimmunol.1400322 – volume: 10 year: 2019 ident: CR77 article-title: Cancer-associated fibroblasts enhance tumor-associated macrophages enrichment and suppress NK cells function in colorectal cancer publication-title: Cell Death Dis. doi: 10.1038/s41419-019-1435-2 – volume: 6 start-page: 990 year: 2018 end-page: 1000 ident: CR70 article-title: T cell–inflamed versus non-T cell–inflamed tumors: a conceptual framework for cancer immunotherapy drug development and combination therapy selection publication-title: Cancer Immunol. Res. doi: 10.1158/2326-6066.CIR-18-0277 – volume: 77 start-page: 237 year: 2017 end-page: 245 ident: CR53 article-title: Chimeric antigen receptor (CAR) T cells: lessons learned from targeting of CD19 in B-cell malignancies publication-title: Drugs doi: 10.1007/s40265-017-0690-8 – volume: 8 year: 2018 ident: CR61 article-title: Engineering Axl specific CAR and SynNotch receptor for cancer therapy publication-title: Sci. Rep. doi: 10.1038/s41598-018-22252-6 – volume: 3 start-page: 116 year: 2020 ident: CR62 article-title: Engineering of an enhanced synthetic Notch receptor by reducing ligand-independent activation publication-title: Commun. Biol. doi: 10.1038/s42003-020-0848-x – volume: 348 start-page: 74 year: 2015 end-page: 80 ident: CR81 article-title: T cell exclusion, immune privilege, and the tumor microenvironment publication-title: Science doi: 10.1126/science.aaa6204 – volume: 13 start-page: e0200725 year: 2018 ident: CR16 article-title: The phosphoinositide-3 kinase (PI3K)-δ,γ inhibitor, duvelisib shows preclinical synergy with multiple targeted therapies in hematologic malignancies publication-title: PLoS ONE doi: 10.1371/journal.pone.0200725 – volume: 165 start-page: 100 year: 2016 end-page: 110 ident: CR17 article-title: Cytotoxic T cells use mechanical force to potentiate target cell killing publication-title: Cell doi: 10.1016/j.cell.2016.01.021 – ident: CR24 – volume: 57 start-page: 860 year: 2015 end-page: 872 ident: CR92 article-title: Limited mitochondrial permeabilization causes DNA damage and genomic instability in the absence of cell death publication-title: Mol. Cell doi: 10.1016/j.molcel.2015.01.018 – volume: 319 start-page: 2747 year: 2013 end-page: 2757 ident: CR90 article-title: Qualitative changes in the proteome of extracellular vesicles accompanying cancer cell transition to mesenchymal state publication-title: Exp. Cell Res. doi: 10.1016/j.yexcr.2013.08.003 – volume: 14 start-page: 1014 year: 2013 end-page: 1022 ident: CR65 article-title: Innate and adaptive immune cells in the tumor microenvironment publication-title: Nat. Immunol. doi: 10.1038/ni.2703 – volume: 2019 start-page: 5245034 year: 2019 ident: CR100 article-title: Combinatorial approach to improve cancer immunotherapy: rational drug design strategy to simultaneously hit multiple targets to kill tumor cells and to activate the immune system publication-title: J. Oncol. doi: 10.1155/2019/5245034 – volume: 13 start-page: 396 year: 2018 end-page: 406 ident: CR56 article-title: CAR-T cell therapy for acute lymphoblastic leukemia: transforming the treatment of relapsed and refractory disease publication-title: Curr. Hematol. Malig. Rep. doi: 10.1007/s11899-018-0470-x – volume: 66 start-page: 551 year: 2017 end-page: 564 ident: CR41 article-title: PD-1 and PD-L1 antibodies in cancer: current status and future directions publication-title: Cancer Immunol. Immunother. doi: 10.1007/s00262-017-1954-6 – volume: 14 start-page: 15 year: 2016 end-page: 23 ident: CR93 article-title: Therapeutic targeting of autophagy publication-title: EBioMedicine doi: 10.1016/j.ebiom.2016.10.034 – volume: 22 start-page: 343 year: 2018 end-page: 351 ident: CR28 article-title: Inducible co-stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy publication-title: Expert Opin. Ther. Targets doi: 10.1080/14728222.2018.1444753 – volume: 6 start-page: 441 year: 2015 ident: CR7 article-title: Structural features of the αβTCR mechanotransduction apparatus that promote pMHC discrimination publication-title: Front. Immunol. doi: 10.3389/fimmu.2015.00441 – volume: 86 start-page: 8161 year: 2012 end-page: 8170 ident: CR25 article-title: Progressive loss of memory T cell potential and commitment to exhaustion during chronic viral infection publication-title: J. Virol. doi: 10.1128/JVI.00889-12 – volume: 10 start-page: 1835 year: 2019 ident: CR78 article-title: The dark side of fibroblasts: cancer-associated fibroblasts as mediators of immunosuppression in the tumor microenvironment publication-title: Front. Immunol. doi: 10.3389/fimmu.2019.01835 – volume: 9 year: 2018 ident: CR84 article-title: Cancer-associated fibroblasts induce antigen-specific deletion of CD8+ T cells to protect tumour cells publication-title: Nat. Commun. doi: 10.1038/s41467-018-03347-0 – volume: 387 start-page: 630 year: 1997 end-page: 634 ident: CR13 article-title: Crystal structure of the complex between CD8 alpha-alpha and HLA-A2 publication-title: Nature doi: 10.1038/42523 – volume: 36 start-page: 773 year: 2018 end-page: 779 ident: CR45 article-title: Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair–deficient/microsatellite instability–high metastatic colorectal cancer publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2017.76.9901 – volume: 9 year: 2018 ident: CR74 article-title: Cancer-derived exosomal miR-25-3p promotes pre-metastatic niche formation by inducing vascular permeability and angiogenesis publication-title: Nat. Commun. doi: 10.1038/s41467-018-07810-w – volume: 117 start-page: 451 year: 2017 end-page: 460 ident: CR2 article-title: HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer publication-title: Br. J. Cancer doi: 10.1038/bjc.2017.220 – volume: 378 start-page: 2078 year: 2018 end-page: 2092 ident: CR46 article-title: Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1801005 – volume: 384 start-page: 577 year: 1996 end-page: 581 ident: CR12 article-title: CD8 enhances formation of stable T-cell receptor/MHC class I molecule complexes publication-title: Nature doi: 10.1038/384577a0 – volume: 103 start-page: 10985 year: 2006 end-page: 10990 ident: CR20 article-title: Cytotoxic T lymphocytes kill multiple targets simultaneously via spatiotemporal uncoupling of lytic and stimulatory synapses publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.0600651103 – volume: 33 start-page: 547 year: 2018 end-page: 562 ident: CR69 article-title: T cell dysfunction in cancer publication-title: Cancer Cell doi: 10.1016/j.ccell.2018.03.012 – volume: 9 start-page: 1816 year: 2018 ident: CR23 article-title: Metabolic checkpoints: novel avenues for immunotherapy of cancer publication-title: Front. Immunol. doi: 10.3389/fimmu.2018.01816 – volume: 97 start-page: 31 year: 2015 end-page: 38 ident: CR5 article-title: CD4+/CD8+ double-positive T cells: more than just a developmental stage? publication-title: J. Leukoc. Biol. doi: 10.1189/jlb.1RU0814-382 – volume: 12 start-page: 213 year: 2015 end-page: 226 ident: CR101 article-title: Exploiting the critical perioperative period to improve long-term cancer outcomes publication-title: Nat. Rev. Clin. Oncol. doi: 10.1038/nrclinonc.2014.224 – volume: 9 start-page: 5 year: 2012 end-page: 6 ident: CR18 article-title: Endocytosis by target cells: an essential means for perforin- and granzyme-mediated killing publication-title: Cell. Mol. Immunol. doi: 10.1038/cmi.2011.45 – volume: 4 start-page: 1129 year: 2012 end-page: 1138 ident: CR82 article-title: Cancer-associated fibroblasts as targets for immunotherapy publication-title: Immunotherapy doi: 10.2217/imt.12.112 – volume: 30 start-page: 219 year: 2019 end-page: 235 ident: CR99 article-title: Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors publication-title: Ann. Oncol. doi: 10.1093/annonc/mdy551 – volume: 61 start-page: 602 year: 2016 end-page: 613 ident: CR19 article-title: Structural basis and functional role of intramembrane trimerization of the Fas/CD95 death receptor publication-title: Mol. Cell doi: 10.1016/j.molcel.2016.01.009 – volume: 176 start-page: 775 year: 2019 end-page: 789 ident: CR26 article-title: Dysfunctional CD8 T Cells form a proliferative, dynamically regulated compartment within human melanoma publication-title: Cell doi: 10.1016/j.cell.2018.11.043 – volume: 115 start-page: 108921 year: 2019 ident: CR85 article-title: Intrinsic β-catenin signaling suppresses CD8+ T-cell infiltration in colorectal cancer publication-title: Biomed. Pharmacother. doi: 10.1016/j.biopha.2019.108921 – volume: 7 start-page: 45 year: 2014 end-page: 52 ident: CR91 article-title: Autophagy controls the kinetics and extent of mitochondrial apoptosis by regulating PUMA levels publication-title: Cell Rep. doi: 10.1016/j.celrep.2014.02.036 – volume: 410 start-page: 127 year: 2017 end-page: 156 ident: CR27 article-title: Tim-3, Lag-3, and TIGIT publication-title: Curr. Top. Microbiol. Immunol. – volume: 18 year: 2019 ident: CR88 article-title: Exosome-orchestrated hypoxic tumor microenvironment publication-title: Mol. Cancer doi: 10.1186/s12943-019-0982-6 – volume: 369 start-page: 134 year: 2013 end-page: 144 ident: CR39 article-title: Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1305133 – volume: 19 start-page: 133 year: 2019 end-page: 150 ident: CR36 article-title: The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy publication-title: Nat. Rev. Cancer doi: 10.1038/s41568-019-0116-x – volume: 164 start-page: 770 year: 2016 end-page: 779 ident: CR60 article-title: Precision tumor recognition by T cells with combinatorial antigen-sensing circuits publication-title: Cell doi: 10.1016/j.cell.2016.01.011 – volume: 12 start-page: 683 year: 2020 ident: CR98 article-title: Adoptive cell therapy—harnessing antigen-specific T cells to target solid tumours publication-title: Cancers doi: 10.3390/cancers12030683 – volume: 19 start-page: 5 year: 2018 end-page: 18 ident: CR51 article-title: CAR T-cell therapy: a new era in cancer immunotherapy publication-title: Curr. Pharm. Biotechnol. doi: 10.2174/1389201019666180418095526 – volume: 25 start-page: 176 year: 2018 end-page: 191 ident: CR57 article-title: Fludarabine and neurotoxicity in engineered T-cell therapy publication-title: Gene Ther. doi: 10.1038/s41434-018-0019-6 – volume: 48 start-page: 399 year: 2018 end-page: 416 ident: CR1 article-title: Cancer-cell-intrinsic mechanisms shaping the tumor immune landscape publication-title: Immunity doi: 10.1016/j.immuni.2018.03.004 – volume: 153 start-page: 42 year: 2018 end-page: 50 ident: CR11 article-title: Selected signalling proteins recruited to the T-cell receptor-CD3 complex publication-title: Immunology doi: 10.1111/imm.12809 – volume: 16 start-page: 599 year: 2016 ident: CR80 article-title: Regulatory circuits of T cell function in cancer publication-title: Nat. Rev. Immunol. doi: 10.1038/nri.2016.80 – volume: 135 start-page: 1228 year: 2008 end-page: 1237 ident: CR83 article-title: PD-1 ligand expression by human colonic myofibroblasts/fibroblasts regulates CD4+ T-cell activity publication-title: Gastroenterology doi: 10.1053/j.gastro.2008.07.016 – volume: 41 start-page: 21 year: 2019 end-page: 30 ident: CR37 article-title: Developing combination strategies using PD-1 checkpoint inhibitors to treat cancer publication-title: Semin. Immunopathol. doi: 10.1007/s00281-018-0714-9 – volume: 8 start-page: 66 year: 2018 ident: CR73 article-title: The origin and functions of exosomes in cancer publication-title: Front. Oncol. doi: 10.3389/fonc.2018.00066 – volume: 8 start-page: 51936 year: 2017 end-page: 51945 ident: CR31 article-title: PD1 signal transduction pathways in T cells publication-title: Oncotarget doi: 10.18632/oncotarget.17232 – volume: 3 start-page: e1920833 year: 2020 end-page: e1920833 ident: CR49 article-title: Assessment of clinical activity of PD-1 checkpoint inhibitor combination therapies reported in clinical trials publication-title: JAMA Netw. Open doi: 10.1001/jamanetworkopen.2019.20833 – volume: 352 start-page: 175 year: 2016 end-page: 180 ident: CR89 article-title: Hypoxic control of metastasis publication-title: Science doi: 10.1126/science.aaf4405 – volume: 105 start-page: 15016 year: 2008 end-page: 15021 ident: CR64 article-title: Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.0801497105 – volume: 25 start-page: 3074 year: 2019 end-page: 3083 ident: CR86 article-title: WNT/β-catenin pathway activation correlates with immune exclusion across human cancers publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-18-1942 – volume: 18 start-page: 408 year: 2019 end-page: 410 ident: CR95 article-title: Anticancer autophagy inhibitors attract ‘resurgent’ interest publication-title: Nat. Rev. Drug Discov. doi: 10.1038/d41573-019-00072-1 – volume: 97 start-page: 31 year: 2015 ident: 1048_CR5 publication-title: J. Leukoc. Biol. doi: 10.1189/jlb.1RU0814-382 – volume: 8 start-page: 894 year: 2017 ident: 1048_CR14 publication-title: Front. Immunol. doi: 10.3389/fimmu.2017.00894 – volume: 30 start-page: 219 year: 2019 ident: 1048_CR99 publication-title: Ann. Oncol. doi: 10.1093/annonc/mdy551 – volume: 11 start-page: 2 year: 2018 ident: 1048_CR103 publication-title: Cancers doi: 10.3390/cancers11010002 – volume: 6 start-page: 990 year: 2018 ident: 1048_CR70 publication-title: Cancer Immunol. Res. doi: 10.1158/2326-6066.CIR-18-0277 – volume: 19 start-page: 5 year: 2018 ident: 1048_CR51 publication-title: Curr. Pharm. Biotechnol. doi: 10.2174/1389201019666180418095526 – volume: 48 start-page: 399 year: 2018 ident: 1048_CR1 publication-title: Immunity doi: 10.1016/j.immuni.2018.03.004 – volume: 13 start-page: 396 year: 2018 ident: 1048_CR56 publication-title: Curr. Hematol. Malig. Rep. doi: 10.1007/s11899-018-0470-x – volume: 94 start-page: 25 year: 2013 ident: 1048_CR35 publication-title: J. Leukoc. Biol. doi: 10.1189/jlb.1212621 – volume: 17 start-page: 854 year: 2018 ident: 1048_CR97 publication-title: Nat. Rev. Drug Discov. doi: 10.1038/nrd.2018.210 – volume: 2018 start-page: 2386187 year: 2018 ident: 1048_CR58 publication-title: J. Immunol. Res. – volume: 135 start-page: 1228 year: 2008 ident: 1048_CR83 publication-title: Gastroenterology doi: 10.1053/j.gastro.2008.07.016 – volume: 12 start-page: 213 year: 2015 ident: 1048_CR101 publication-title: Nat. Rev. Clin. Oncol. doi: 10.1038/nrclinonc.2014.224 – volume: 378 start-page: 2078 year: 2018 ident: 1048_CR46 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1801005 – volume: 8 start-page: 730 year: 2018 ident: 1048_CR87 publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-17-1327 – volume: 41 start-page: 21 year: 2019 ident: 1048_CR37 publication-title: Semin. Immunopathol. doi: 10.1007/s00281-018-0714-9 – volume: 117 start-page: 451 year: 2017 ident: 1048_CR2 publication-title: Br. J. Cancer doi: 10.1038/bjc.2017.220 – volume: 7 start-page: 45 year: 2014 ident: 1048_CR91 publication-title: Cell Rep. doi: 10.1016/j.celrep.2014.02.036 – volume: 10 start-page: 2103 year: 2019 ident: 1048_CR76 publication-title: Front. Immunol. doi: 10.3389/fimmu.2019.02103 – volume: 14 start-page: 15 year: 2016 ident: 1048_CR93 publication-title: EBioMedicine doi: 10.1016/j.ebiom.2016.10.034 – volume: 2 start-page: e192535 year: 2019 ident: 1048_CR42 publication-title: JAMA Netw. Open doi: 10.1001/jamanetworkopen.2019.2535 – volume: 2 start-page: 1023 year: 2014 ident: 1048_CR8 publication-title: Cancer Immunol. Res. doi: 10.1158/2326-6066.CIR-14-0161 – volume: 19 start-page: 133 year: 2019 ident: 1048_CR36 publication-title: Nat. Rev. Cancer doi: 10.1038/s41568-019-0116-x – volume: 25 start-page: 3747 year: 2018 ident: 1048_CR102 publication-title: Ann. Surg. Oncol. doi: 10.1245/s10434-018-6691-3 – volume: 176 start-page: 775 year: 2019 ident: 1048_CR26 publication-title: Cell doi: 10.1016/j.cell.2018.11.043 – volume: 27 start-page: 843 year: 2020 ident: 1048_CR94 publication-title: Cell Death Differ. doi: 10.1038/s41418-019-0474-7 – volume: 11 year: 2012 ident: 1048_CR66 publication-title: Mol. Cancer doi: 10.1186/1476-4598-11-81 – volume: 8 start-page: 66 year: 2018 ident: 1048_CR73 publication-title: Front. Oncol. doi: 10.3389/fonc.2018.00066 – volume: 18 start-page: 408 year: 2019 ident: 1048_CR95 publication-title: Nat. Rev. Drug Discov. doi: 10.1038/d41573-019-00072-1 – volume: 387 start-page: 630 year: 1997 ident: 1048_CR13 publication-title: Nature doi: 10.1038/42523 – volume: 115 start-page: 108921 year: 2019 ident: 1048_CR85 publication-title: Biomed. Pharmacother. doi: 10.1016/j.biopha.2019.108921 – volume: 25 start-page: 3074 year: 2019 ident: 1048_CR86 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-18-1942 – volume: 105 start-page: 15016 year: 2008 ident: 1048_CR64 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.0801497105 – volume: 2019 start-page: 5245034 year: 2019 ident: 1048_CR100 publication-title: J. Oncol. doi: 10.1155/2019/5245034 – volume: 384 start-page: 577 year: 1996 ident: 1048_CR12 publication-title: Nature doi: 10.1038/384577a0 – volume: 9 start-page: 5 year: 2012 ident: 1048_CR18 publication-title: Cell. Mol. Immunol. doi: 10.1038/cmi.2011.45 – volume: 10 start-page: 1835 year: 2019 ident: 1048_CR78 publication-title: Front. Immunol. doi: 10.3389/fimmu.2019.01835 – volume: 57 start-page: 860 year: 2015 ident: 1048_CR92 publication-title: Mol. Cell doi: 10.1016/j.molcel.2015.01.018 – volume: 61 start-page: 602 year: 2016 ident: 1048_CR19 publication-title: Mol. Cell doi: 10.1016/j.molcel.2016.01.009 – volume: 8 year: 2018 ident: 1048_CR61 publication-title: Sci. Rep. doi: 10.1038/s41598-018-22252-6 – volume: 13 start-page: e0200725 year: 2018 ident: 1048_CR16 publication-title: PLoS ONE doi: 10.1371/journal.pone.0200725 – volume: 25 start-page: 176 year: 2018 ident: 1048_CR57 publication-title: Gene Ther. doi: 10.1038/s41434-018-0019-6 – volume: 6 start-page: 441 year: 2015 ident: 1048_CR7 publication-title: Front. Immunol. doi: 10.3389/fimmu.2015.00441 – volume: 19 start-page: 1236 year: 2018 ident: 1048_CR75 publication-title: Nat. Immunol. doi: 10.1038/s41590-018-0229-5 – volume: 19 start-page: 185 year: 2020 ident: 1048_CR50 publication-title: Nat. Rev. Drug Discov. doi: 10.1038/s41573-019-0051-2 – volume: 8 start-page: 51936 year: 2017 ident: 1048_CR31 publication-title: Oncotarget doi: 10.18632/oncotarget.17232 – volume: 201 start-page: 14 year: 2018 ident: 1048_CR6 publication-title: Immunol. Lett. doi: 10.1016/j.imlet.2018.11.004 – volume: 76 start-page: 6445 year: 2016 ident: 1048_CR96 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-16-1311 – volume: 103 start-page: 10985 year: 2006 ident: 1048_CR20 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.0600651103 – volume: 22 start-page: 343 year: 2018 ident: 1048_CR28 publication-title: Expert Opin. Ther. Targets doi: 10.1080/14728222.2018.1444753 – volume: 165 start-page: 100 year: 2016 ident: 1048_CR17 publication-title: Cell doi: 10.1016/j.cell.2016.01.021 – volume: 115 start-page: E4041 year: 2018 ident: 1048_CR79 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.1720948115 – volume: 3 start-page: e1920833 year: 2020 ident: 1048_CR49 publication-title: JAMA Netw. Open doi: 10.1001/jamanetworkopen.2019.20833 – volume: 18 year: 2019 ident: 1048_CR88 publication-title: Mol. Cancer doi: 10.1186/s12943-019-0982-6 – volume: 10 year: 2019 ident: 1048_CR77 publication-title: Cell Death Dis. doi: 10.1038/s41419-019-1435-2 – volume: 9 year: 2018 ident: 1048_CR74 publication-title: Nat. Commun. doi: 10.1038/s41467-018-07810-w – volume: 77 start-page: 237 year: 2017 ident: 1048_CR53 publication-title: Drugs doi: 10.1007/s40265-017-0690-8 – volume: 9 year: 2018 ident: 1048_CR84 publication-title: Nat. Commun. doi: 10.1038/s41467-018-03347-0 – volume: 5 start-page: 1614 year: 2019 ident: 1048_CR72 publication-title: JAMA Oncol. doi: 10.1001/jamaoncol.2019.2311 – volume: 319 start-page: 2747 year: 2013 ident: 1048_CR90 publication-title: Exp. Cell Res. doi: 10.1016/j.yexcr.2013.08.003 – volume: 24 start-page: 739 year: 2018 ident: 1048_CR59 publication-title: Nat. Med. doi: 10.1038/s41591-018-0036-4 – volume: 86 start-page: 8161 year: 2012 ident: 1048_CR25 publication-title: J. Virol. doi: 10.1128/JVI.00889-12 – volume: 16 start-page: 599 year: 2016 ident: 1048_CR80 publication-title: Nat. Rev. Immunol. doi: 10.1038/nri.2016.80 – volume: 379 start-page: 2108 year: 2018 ident: 1048_CR48 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1809615 – volume: 193 start-page: 258 year: 2014 ident: 1048_CR9 publication-title: J. Immunol. doi: 10.4049/jimmunol.1400322 – volume: 33 start-page: 547 year: 2018 ident: 1048_CR69 publication-title: Cancer Cell doi: 10.1016/j.ccell.2018.03.012 – volume: 289 start-page: 28514 year: 2014 ident: 1048_CR10 publication-title: J. Biol. Chem. doi: 10.1074/jbc.M114.574319 – volume: 8 start-page: 1467 year: 2017 ident: 1048_CR15 publication-title: Front. Immunol. doi: 10.3389/fimmu.2017.01467 – volume: 352 start-page: 175 year: 2016 ident: 1048_CR89 publication-title: Science doi: 10.1126/science.aaf4405 – volume: 313 start-page: 1972 year: 2006 ident: 1048_CR33 publication-title: Science doi: 10.1126/science.1131078 – volume: 37 start-page: 1049 year: 2019 ident: 1048_CR63 publication-title: Nat. Biotechnol. doi: 10.1038/s41587-019-0192-1 – volume: 36 start-page: 1703 year: 2018 ident: 1048_CR43 publication-title: World J. Urol. doi: 10.1007/s00345-018-2264-0 – volume: 2 start-page: 487 year: 2001 ident: 1048_CR34 publication-title: Nat. Immunol. doi: 10.1038/88678 – volume: 45 start-page: 60 year: 2017 ident: 1048_CR29 publication-title: Curr. Opin. Immunol. doi: 10.1016/j.coi.2017.01.005 – volume: 367 start-page: eaba7365 year: 2020 ident: 1048_CR3 publication-title: Science doi: 10.1126/science.aba7365 – volume: 12 start-page: 683 year: 2020 ident: 1048_CR98 publication-title: Cancers doi: 10.3390/cancers12030683 – volume: 3 start-page: 116 year: 2020 ident: 1048_CR62 publication-title: Commun. Biol. doi: 10.1038/s42003-020-0848-x – volume: 7 start-page: 1184 year: 2017 ident: 1048_CR67 publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-17-0250 – ident: 1048_CR24 doi: 10.1126/science.aau0135 – volume: 9 start-page: 1816 year: 2018 ident: 1048_CR23 publication-title: Front. Immunol. doi: 10.3389/fimmu.2018.01816 – volume: 164 start-page: 770 year: 2016 ident: 1048_CR60 publication-title: Cell doi: 10.1016/j.cell.2016.01.011 – volume: 11 start-page: 6505 year: 2018 ident: 1048_CR30 publication-title: Onco. Targets Ther. doi: 10.2147/OTT.S150817 – volume: 380 start-page: 1103 year: 2019 ident: 1048_CR44 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1816047 – volume: 4 start-page: 1129 year: 2012 ident: 1048_CR82 publication-title: Immunotherapy doi: 10.2217/imt.12.112 – volume: 163 start-page: 1215 year: 2003 ident: 1048_CR22 publication-title: Am. J. Pathol. doi: 10.1016/S0002-9440(10)63481-5 – volume: 6 year: 2015 ident: 1048_CR32 publication-title: Nat. Commun. doi: 10.1038/ncomms7692 – volume: 20 start-page: 1283 year: 2019 ident: 1048_CR54 publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms20061283 – volume: 18 start-page: 197 year: 2019 ident: 1048_CR71 publication-title: Nat. Rev. Drug Discov. doi: 10.1038/s41573-018-0007-y – volume: 369 start-page: 134 year: 2013 ident: 1048_CR39 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1305133 – volume: 7 year: 2016 ident: 1048_CR21 publication-title: Nat. Commun. doi: 10.1038/ncomms10823 – volume: 7 start-page: 278 year: 2019 ident: 1048_CR40 publication-title: J. Immunother. Cancer doi: 10.1186/s40425-019-0768-9 – volume: 410 start-page: 127 year: 2017 ident: 1048_CR27 publication-title: Curr. Top. Microbiol. Immunol. – volume: 21 start-page: e168 year: 2020 ident: 1048_CR52 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(19)30823-X – volume: 348 start-page: 74 year: 2015 ident: 1048_CR81 publication-title: Science doi: 10.1126/science.aaa6204 – volume: 36 start-page: 773 year: 2018 ident: 1048_CR45 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2017.76.9901 – volume: 66 start-page: 551 year: 2017 ident: 1048_CR41 publication-title: Cancer Immunol. Immunother. doi: 10.1007/s00262-017-1954-6 – volume: 13 start-page: 5426 year: 2007 ident: 1048_CR55 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-07-0674 – volume: 40 start-page: 142 year: 2019 ident: 1048_CR38 publication-title: Trends Immunol. doi: 10.1016/j.it.2018.12.003 – volume: 14 start-page: 1014 year: 2013 ident: 1048_CR65 publication-title: Nat. Immunol. doi: 10.1038/ni.2703 – volume: 153 start-page: 42 year: 2018 ident: 1048_CR11 publication-title: Immunology doi: 10.1111/imm.12809 – volume: 379 start-page: 2220 year: 2018 ident: 1048_CR47 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1809064 – volume: 6 start-page: 827 year: 2016 ident: 1048_CR68 publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-15-1545 – volume: 18 year: 2019 ident: 1048_CR4 publication-title: Mol. Cancer doi: 10.1186/s12943-019-1091-2 |
| SSID | ssj0009087 |
| Score | 2.7408137 |
| SecondaryResourceType | review_article |
| Snippet | The functions of, and interactions between, the innate and adaptive immune systems are vital for anticancer immunity. Cytotoxic T cells expressing cell-surface... |
| SourceID | pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 359 |
| SubjectTerms | 631/80/86/2371 692/4028/67/1059/2325 692/4028/67/327 Adverse events Animals Biomedical and Life Sciences Biomedicine Cancer Cancer immunotherapy Cancer Research CD8 antigen Cell surface Clinical trials Cytotoxicity Drug Resistance Epidemiology Humans Immune checkpoint inhibitors Immunotherapy Immunotherapy - methods Lymphocytes Lymphocytes T Molecular Medicine Neoplasms - immunology Oncology Receptor mechanisms Review Review Article T-Lymphocytes, Cytotoxic - immunology |
| Title | Cytotoxic CD8+ T cells in cancer and cancer immunotherapy |
| URI | https://link.springer.com/article/10.1038/s41416-020-01048-4 https://www.ncbi.nlm.nih.gov/pubmed/32929195 https://www.proquest.com/docview/2477090156 https://www.proquest.com/docview/2442848171 https://pubmed.ncbi.nlm.nih.gov/PMC7853123 |
| Volume | 124 |
| WOSCitedRecordID | wos000569286500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1532-1827 dateEnd: 20211231 omitProxy: false ssIdentifier: ssj0009087 issn: 0007-0920 databaseCode: M7P dateStart: 20190101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1532-1827 dateEnd: 20211231 omitProxy: false ssIdentifier: ssj0009087 issn: 0007-0920 databaseCode: 7X7 dateStart: 20190101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1532-1827 dateEnd: 20211231 omitProxy: false ssIdentifier: ssj0009087 issn: 0007-0920 databaseCode: 7RV dateStart: 20190101 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1532-1827 dateEnd: 20211231 omitProxy: false ssIdentifier: ssj0009087 issn: 0007-0920 databaseCode: BENPR dateStart: 20190101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1532-1827 dateEnd: 20211231 omitProxy: false ssIdentifier: ssj0009087 issn: 0007-0920 databaseCode: 8C1 dateStart: 20190101 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR3LatwwcGiSUnpp-o7bdHGht1REsiVLOpVmk9BDuywhDXszsiwTQ7GTtVOav68ky7tsQnPpRQgkYWse0rw0A_CJVhk1BauQMDxFVBGDJFcMkURLkSnGjC_ad_Gdz2ZisZDzYHDrQljleCb6g7pstbORHyaUc-wur-zL1TVyVaOcdzWU0NiCHZclIfGhe_N10l0shpyZzhwnExwezeBUHHaUWFEEOeXJaSQC0c2L6Z60eT9o8o7n1F9Ip7v_u5Xn8CyIovHXgXZewCPTvIQnP4Kz_RXI6W3f9u2fWsfTY3EQn8fOyt_FdRNrRyvLWDXl2K3dO5Pwmuv2Nfw8PTmffkOh0gLSlNMecaozXeiKG4W5odQoatmxKKqMaJZpxitaKQtAq05RrFVJaaESXKS6FKkxqUrfwHbTNmYPYkZ0UUqTsLKyWjfLrP5lKsyMkFaysMsiICOYcx3SkLtqGL9y7w5PRT6gJreoyT1qchrBwWrN1ZCE48HZ-yPY88CQXb6GeQQfV8OWlRzkVGPaGzfH6mJUEE4ieDsge_W5NLFyJJEsAr5BBqsJLk335khTX_p03dxKRFY-iODzSDDr3_r3Lt49vIv38DRx0TWYICL3Ybtf3pgP8Fj_7utuOYEtfnbh2gX3rbCtmJIJ7BydzOZnE88mfwGMhxDv |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VgoBLeZWSUiBIcCpW48SO7QNCaEvVqtsVhwX1FhzHUSNVSdmkwP4pfiOePHa1VPTWA7dIfsSPz-MZzwvgDctjZlOeE2lFRJimliihOaGhUTLWnNs2ad_XsZhM5Omp-rwGvwdfGDSrHGhiS6izyuAb-V7IhAjw8oo_XHwnmDUKtatDCo0OFsd2_tOJbPX7o323v2_D8ODTdHRI-qwCxDDBGiKYiU1qcmF1ICxjVjMHvTTNY2p4bLjIWa5ViKIDC4zOGEt1GKSRyWRkbaQj1-8tuI2R7PBEydHSpEQFsovRic9_roveSSeI5F7NqGN9CAprKAFJwlYvwivc7VUjzb80te0FePDgf1u6h7DRs9r-x-5sPII1Wz6Guye9McETUKN5UzXVr8L4o32560991GLUflH6Bs_CzNdlNnwW6EfTe6vNN-HLjQz8KayXVWmfgc-pSTNlQ57lwtG72MmXNg-4lcpxTq6ZB3TY1sT0YdYx28d50qr7I5l0UEgcFJIWCgnzYHfR5qILMnJt7Z1hm5Oe4NTJco89eL0odqQCV06XtrrEOk7WZJIK6sFWB67F76LQ8clUcQ_ECuwWFTAM-WpJWZy14ciF4_gc_-PBuwGgy2H9exbb18_iFdw7nJ6Mk_HR5Pg53A_RkiighKodWG9ml_YF3DE_mqKevWyPoA_fbhq4fwA9LmsT |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VLaq48H6EFggSnIq1cTKOnUNVwW5XVC2rFSqot9RxHBEJJWWTAvvX-uuw89jVUtFbD9wi-RHb83k8Y88D4A1mIeqEZURoHhCUVJOIS0aoryIRSsZ0k7Tv6zGfTsXpaTTbgMveF8aaVfY8sWHUaansHfnQR849e3iFw6wzi5iNJ_vnP4jNIGVfWvt0Gi1EjvTil1Hfqr3DsaH1W9-fHJyMPpIuwwBRyLEmHFWoEpVxLT2uEbVEA8MkyUKqWKgYzzCTkW_VCPSUTBET6XtJoFIRaB3IwPR7Cza5ETJwAJsfDqazz6uQv55oI3bay0DTSeey4wViWCE1ghCxqpvVhwTB9WPxiqx71WTzr3fb5jic3PufF_I-3O2EcPd9u2sewIYuHsLWp87M4BFEo0Vd1uXvXLmjsdh1T1z7vlG5eeEqu0vmrizS_jO3HjadH9viMXy5kYE_gUFRFvoZuIyqJI20z9KMG04YGs1TZx7TIjIylWnmAO1JHKsuALvNA_I9bgwBAhG3sIgNLOIGFjE6sLtsc96GH7m29k5P8rhjRVW8orcDr5fFhonYlZOFLi9sHaOFoqCcOvC0Bdryd4FvJGgaMQf4GgSXFWyA8vWSIv_WBCrnRhY0kpED73qwrob171k8v34Wr2DL4DU-PpwebcMd35oYeZTQaAcG9fxCv4Db6medV_OX3X504eymkfsHwjZ1cQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cytotoxic+CD8%2B+T+cells+in+cancer+and+cancer+immunotherapy&rft.jtitle=British+journal+of+cancer&rft.au=Raskov%2C+Hans&rft.au=Orhan%2C+Adile&rft.au=Christensen%2C+Jan+Pravsgaard&rft.au=G%C3%B6genur%2C+Ismail&rft.date=2021-01-19&rft.pub=Nature+Publishing+Group+UK&rft.issn=0007-0920&rft.eissn=1532-1827&rft.volume=124&rft.issue=2&rft.spage=359&rft.epage=367&rft_id=info:doi/10.1038%2Fs41416-020-01048-4&rft_id=info%3Apmid%2F32929195&rft.externalDocID=PMC7853123 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0007-0920&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0007-0920&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0007-0920&client=summon |